改訂4版 MFICUマニュアル

出版社: メディカ出版
著者:
発行日: 2022-06-10
分野: 臨床医学:内科  >  周産期(新生児)
ISBN: 9784840478731
電子書籍版: 2022-06-10 (電子書籍版)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

15,400 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

商品紹介

母体・胎児ICU/MFICUで対応する事項に絞り込み、国内外の最新知識を盛り込んだ待望の改訂4版/全国周産期医療(MFICU)連絡協議会の幹事らが丁寧に査読を行い、確かな内容を収載/追加項目:「特定妊婦・社会的ハイリスク妊娠の対応」「周産期医療における診断・治療の思考過程」「生殖医療と周産期医療」「妊娠前に与えるべき情報―プレコンセプショナルコンサルテーション、薬剤―」「胎児・新生児の管理:診断のアプローチ」等
産婦人科医に必須の母体・胎児管理を解説
MFICUで対応する事項にフォーカスし、国内外の最新知識を盛り込んだ待望の新版。妊娠・分娩・産褥期における母体・胎児の異常について、管理・診断・治療を解説。「産婦人科診療ガイドライン:産科編2020」に対応。

目次

  • 【第1章】周産期医療概論
    ●1. わが国の周産期医療体制の現状と課題
    ●2. 総合周産期母子医療センターの認定と今後
    ●3. 産科医療補償制度の概要
    ●4. 妊産婦死亡の対応と母体安全への提言
    ●5. 胎児治療の現状と課題
    ●6. 特定妊婦・社会的ハイリスク妊娠の対応
    ●7. 災害対策・BCP
    ●8. 周産期医療における診断・治療の思考過程
    ●9. 生殖医療と周産期医療


    【第2章】母体の管理
    ■I. 合併症妊娠(妊娠前からの内科/外科合併症)
    ●1. 心血管疾患-先天性心疾患,心筋症,不整脈,弁置換後や弁膜症など-
    1. 心疾患(不整脈を除く)
    2. 不整脈
    3. 高血圧合併妊娠
    ●2. 脳血管疾患-もやもや病,AVM,SAH-
    1. 脳出血
    2. 脳梗塞
    ●3. 血液疾患-ITP,貧血-
    1. 特発性(免疫性)血小板減少性紫斑病(ITP)
    2. 貧血
    ●4. 腎疾患-IgA腎症,ネフローゼ,CKD,腎移植後妊娠,血液透析中の妊婦-
    1. IgA腎症
    2. ネフローゼ症候群
    3. 慢性腎臓病(chronic kidney disease;CKD)
    4. 腎移植後妊娠
    5. 血液透析中の妊婦
    ●5. 肝・胆・膵疾患-胆石,胆道閉鎖症術後,肝移植後-
    1. 胆石
    2. 胆道閉鎖症術後妊娠
    3. 肝移植後妊娠
    ●6. 消化器疾患-炎症性腸疾患,過敏性腸症候群,虫垂炎-
    1. 炎症性腸疾患(潰瘍性大腸炎,クローン病)
    2. 過敏性腸症候群
    3. 虫垂炎
    ●7. 呼吸器疾患-気管支喘息-
    ●8. 糖尿病-Ⅰ型,Ⅱ型,劇症型(劇症Ⅰ型糖尿病)-
    ●9. 甲状腺疾患-機能亢進症,機能低下症,甲状腺がん-
    1. 顕性甲状腺機能亢進症(overt hyperthyroidism)
    2. 甲状腺機能低下症
    3. 産褥性甲状腺炎(PPT)
    4. 甲状腺結節と甲状腺がん
    ●10. 自己免疫疾患-SLE,抗リン脂質抗体症候群-
    ●11. 精神神経疾患-統合失調症,てんかん,うつ,不安神経症-
    ●12. 婦人科疾患-子宮頸癌・子宮頸部上皮内腫瘍,卵巣腫瘍,子宮筋腫,胞状奇胎娩出後-
    1. 子宮頸癌・子宮頸部上皮内腫瘍(CIN)
    2. 卵巣腫瘍
    3. 子宮筋腫
    4. 胞状奇胎娩出後
    ●13. 悪性腫瘍-乳がん,白血病-
    1. 乳がん
    2. 白血病
    ●14. 妊娠前に与えるべき情報-プレコンセプショナルコンサルテーション,薬剤-

    ■II. 産科合併症(妊娠に伴って発症した併発症)
    ●1. 後期流産-頸管無力症,巨大絨毛膜下血腫-
    1. 頸管無力症
    2. 巨大絨毛膜下血腫
    3. 流産
    ●2. 異所性妊娠-頸管妊娠,帝王切開瘢痕部妊娠-
    ●3. 切迫早産・前期破水
    1. 切迫早産
    2. 前期破水
    ●4. 妊娠糖尿病
    ●5. 妊娠高血圧症候群-子癇,HELLP症候群-
    1. 妊娠高血圧症候群
    2. HELLP症候群
    ●6. 前置胎盤・癒着胎盤
    ●7. 常位胎盤早期剝離
    ●8. 臍帯異常
    1. 臍帯の発生で起きる異常:
    (1)臍帯卵膜付着・前置血管
    (2)臍帯捻転異常
    (3)単一臍帯動脈
    2. 正常の臍帯に偶発的に発生する異常:
    (1)臍帯巻絡・真結節
    (2)臍帯下垂・脱出
    ●9. 血液型不適合妊娠

    ■III. 周産期感染症
    ●1. 概論-児への感染経路,胎盤や羊水における感染・炎症,triple I-
    ●2. GBS
    ●3. 風疹
    ●4. CMV感染症
    ●5. トキソプラズマ
    ●6. 結核
    ●7. 梅毒
    ●8. 麻疹
    ●9. 水痘・帯状疱疹
    ●10. その他の感染症(HBV,HCV,HTLV-1,HIV,インフルエンザ)
    1. B型肝炎
    2. C型肝炎
    3. 成人T細胞白血病
    4. HIV
    5. インフルエンザ

    ■IV. 母体救急症(母体救命に関わる疾患)
    ●1. 出血性ショック
    ●2. 敗血症性ショック
    ●3. 妊婦の心肺停止・死戦期帝王切開
    ●4. 劇症型A群レンサ球菌感染症
    ●5. 周産期心筋症
    ●6. 羊水塞栓症
    ●7. 深部静脈血栓症(DVT)・肺血栓塞栓症(PTE)
    ●8. 意識障害
    ●9. 母体蘇生-JMELS,BLS,ACLS,ICLS-

    ■V. 分娩時の緊急対応
    ●1. 急速遂娩-超緊急帝王切開-
    ●2. 急速遂娩-早産期の帝王切開-
    ●3. 産後出血-弛緩出血,子宮内反症,産道裂傷,凝固異常-
    ●4. 子宮内反症(整復方法)

    ■VI. 経腟分娩時の特殊対応
    ●1. 帝王切開術後経腟分娩(TOLAC)
    ●2. 骨盤位経腟分娩
    ●3. 双胎児経腟分娩
    ●4. 肩甲難産

    ■VII. 産褥
    ●1. 産褥精神障害-PDS,自殺予防・精神科との連携などを含む-
    1. マタニティ・ブルーズ
    2. 産後うつ病
    3. 産後精神病
    ●2. 産褥熱(Toxic Shock Syndromeを含む)


    【第3章】胎児・新生児の管理
    ■I. 概説
    ●1. 診断アプローチ

    ■II. 先天異常・形態異常
    ●1. 頭部・顔面・頸部
    ●2. 胸部-肺,心臓-
    1. 先天性肺気道奇形
    2. 心室中隔欠損症(ventricular septal defect)
    ●3. 腹部-消化器・胆囊・腎-
    1. 消化器
    2. 腎
    ●4. 四肢・骨格

    ■III. 機能異常
    ●1. 胎児機能不全
    ●2. 羊水過多・過少

    ■IV. 発育異常
    ●1. Fetal Growth Restriction
    ●2. Heavy-for-dates

    ■V. 多胎
    ●1. 多胎の妊娠・分娩管理
    ●2. 双胎間輸血症候群(TTTS)
    ●3. 無心体双胎

    ■VI. 胎児貧血・胎児水腫と胎児治療
    ●1. 胎児貧血
    ●2. 胎児水腫
    ●3. 胎児治療-FLP,TAS,RFA,胎児輸血,FETO-
    1. FLP(胎児鏡下胎盤吻合血管レーザー凝固術)
    2. 胎児胸腔-羊水腔シャント術(TAS)
    3. TRAPシークエンスに対するRFA(ラジオ波無心体双胎焼灼術)
    4. 胎児輸血
    5. 最重症胎児横隔膜ヘルニアに対するFETO

    ■VII. 新生児の管理
    ●1. 病的新生児の診断と初期管理
    1. 新生児仮死
    2. 呼吸障害
    3. 無呼吸
    4. チアノーゼ
    5. 早発黄疸
    6. 新生児発作
    7. 嘔吐
    8. 吐血,下血
    9. 体温異常
    10. 細菌感染症・髄膜炎
    11. 特異的顔貌
    12. 性分化疾患
    ●2. 新生児の低体温療法
    ●3. 新生児蘇生法


    【第4章】産科麻酔
    ●1. 無痛分娩
    ●2. 帝王切開術の麻酔

    【付録】
    資料―周産期医療に必要なデータ・検査値・分類―

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 周産期医療概論

P.5 掲載の参考文献
1) 海野信也. "第6章 わが国の周産期医療体制-医療体制整備の経緯・現状・課題・今後の展望". 産婦人科臨床シリーズ 3 : 分娩・産褥期の正常と異常/周産期感染症. 藤井知行総編集. 東京, 中山書店, 2021, 364-72.
2) 厚生労働省. 医療計画のあり方等に関する検討会「新型コロナウイルス感染症対応を踏まえた今後の医療提供体制の構築に向けた考え方. 2020年12月. https://www.mhlw.go.jp/content/10801000/000705708.pdf
P.11 掲載の参考文献
P.17 掲載の参考文献
1) 厚生労働省. 厚生統計に用いる主な比率及び用語の解説. 厚生労働省ホームページ. https://www.mhlw.go.jp/toukei/kaisetu/index-hw.html
2) 石渡勇, 池田智明ほか. 日本の妊産婦を救うために 2015, 東京医学社, 東京, 2015.
3) 日本産婦人科医会 妊産婦死亡症例検討評価委員会. 母体安全への提言 2020. Vol.11. 令和3年9月. https://www.jaog.or.jp/wp/wp-content/uploads/2021/04/botai_2020.pdf
4) 日本産婦人科医会妊産婦死亡報告事業ホームページ. https://www.jaog.or.jp/about/project/document/ns/d
5) 浜松医科大学羊水塞栓症班ホームページ. http://www2.hama-med.ac.jp/w1b/obgy/afe3/new1.html
6) 日本産婦人科医会医療安全部会ホームページ. 母体安全への提言. https://www.jaog.or.jp/about/project/medical-safety/
P.21 掲載の参考文献
1) Sago, H. et al. Fetal therapies as standard prenatal care in Japan. Obstet Gynecol Sci. 63 (2), 2020, 108-16.
2) Sago, H. et al. Fetoscopic laser photocoagulation for twin-twin transfusion syndrome. J Obstet Gynaecol Res. 44, 2018, 831-39.
3) 左合治彦. ここまで進んだ胎児治療 胎児治療総論. 産科と婦人科. 9 (5), 2018, 1013-17.
4) 日本胎児治療グループJapan Fetal Therapy Group. https://fetusjapan.jp/
5) Sago, H. et al. The outcome and prognostic factors of twin-twin transfusion syndrome following fetoscopic laser surgery. Prenat Diagn. 30, 2010, 1185-91.
6) Takahashi, Y., et al. Thoracoamniotic shunting for fetal pleural effusions using a double-basket shunt. Prenat Diagn. 32, 2012, 1282-87.
7) Sugibayashi, R. et al. Forty cases of twin reversed arterial perfusion sequence treated with radio frequency ablation using the multistep coagulation method : a single-center experience. Prenat Diagn. 36, 2016, 437-43.
8) Senat, MV. et al. Endoscopic laser surgery versus serial amniorreduction for severe twin-to-twin transfusion syndrome. N Engl J Med. 351, 2004, 136-44.
9) Adzick, NS. et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 364, 2011, 993-1004.
10) Partridge, EA. et al. An extra-uterine system to physiologically support the extreme premature lamb. Nat Commun. 8, 2017, 15112. doi : 10.1038/ncomms15112.
P.26 掲載の参考文献
1) 平成28 (2016) 年度厚生労働科学研究 総括. 妊婦健康診査および妊娠届を活用したハイリスク妊産婦の把握と効果的な保健指導のあり方に関する研究. 研究代表者 : 光田信明. https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201606004A
2) 日本産科婦人科学会, 日本産婦人科医会編集・監修. "CQ413 未受診妊婦への対応は? " 産婦人科診療ガイドライン-産科編 2020. 東京, 日本産科婦人科学会, 2020, 238-40.
P.34 掲載の参考文献
1) 日本産科婦人科学会/日本産婦人科医会編集・監修. CQ004-3 妊娠・産褥期に深部静脈血栓塞栓症 (DVT) や肺塞栓症 (PTE) の発症を疑ったら? ". 産婦人科診療ガイドライン-産科編 2017. 東京, 日本産科婦人科学会, 2017, 20-25.
2) Weels, PS. et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 349, 2003, 1227-35.
3) Cooper, N., Frain, J 原著. 宮田靖志監訳. ABC of 臨床推論. 東京, 羊土社, 2018, 60-62.
4) Cooper, N., Frain, J 原著. 宮田靖志監訳. ABC of 臨床推論. 東京, 羊土社, 2018, 53.
5) 徳田安春. Dr. 徳田の診断推論講座. 第2版. 東京, 日本医事新報社, 2020, 2-8.
6) 妊産婦死亡症例検討評価委員会日本産婦人科医会. 母体安全への提言 2019 Vol. 10. 令和2年9月.
7) 日本産科婦人科学会/日本産婦人科医会監修・編集. "CQ 302 切迫早産の診断と管理の注意点は? ". 産婦人科診療ガイドライン-産科編 2020. 東京, 日本産科婦人科学会, 2020, 136-41.
8) 日本産科婦人科学会/日本産婦人科医会監修・編集. "CQ 308 常位胎盤早期剥離の診断・管理は? ". 産婦人科診療ガイドライン-産科編 2020. 東京, 日本産科婦人科学会, 2020, 164-67.
P.38 掲載の参考文献
1) 日本産科婦人科学会登録調査小委員会. ARTデータブック 2017年. http://plaza.umin.ac.jp/~jsog-art/2017data_20191015.pdf
2) 石原理. 生殖医療のこれらの課題. 医学と薬学. 76, 2019, 53-56.
3) Savasi, VM. et al. Maternal and fetal outcomes in oocyte donation pregnancies. Hum Reprod Update. 22, 2016, 620-33.
4) Storgaard, M. et al. Obstetric and neonatal complications in pregnancies conceived after oocyte donation : a systematic review and meta-analysis. BJOG. 124, 2017, 561-72.
5) 倉員正光ほか. 当センターにおける卵子提供妊娠の患者背景, 産科合併症と周産期転帰. 産婦人科の実際. 69, 2020, 175-81.
6) 日本癌治療学会編. "総論 CQ1. 挙児希望を有するがん患者に対して, どのような妊孕性に関連する情報を提供". 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京, 金原出版, 2017.
7) Reulen, RC. et al. Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 18, 2009, 2239-47.
8) Sekiguchi, M. et al. Pregnancy outcomes in female childhood cancer survivors : Nationwide survey in Japan. Pediatr Int. 60, 2018, 254-58.
9) Munne, S. et al. Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing. Fertil Steril. 108, 2017, 62-71.
10) 平原史樹. 体外受精治療の問題点 : 新生児異常の実態. 体外受精治療の行方 問題点と将来展望. 臨床婦人科産科. 69, 2015, 726-31.
11) 竹下直樹. 生殖補助医療と遺伝カウンセリング. 最新小児・周産期遺伝医学研究と遺伝カウンセリング. 2019, 240-47 (遺伝子医学 MOOK 別冊).
12) Wennberg, AL. et al. Effect of maternal age on maternal and neonatal outcomes after assisted reproductive technology. Fertil Steril. 106, 2016, 1142-49 e1114.
13) 藤森敬也ほか. ART治療症例の周産期予後調査 :日産婦周産期登録のデータベースを用いて. 産科と婦人科. 89, 2011, 863-69.
14) Mukhopadhaya, N. et al. Reproductive outcomes after in-vitro fertilization. Curr Opin Obstet Gynecol. 19, 2007, 113-19.
15) Jackson, RA. et al. Perinatal outcomes in singletons following in vitro fertilization : a meta-analysis. Obstet Gynecol. 103, 2004, 551-63.
16) Thomopoulos, C. et al. Assisted reproductive technology and pregnancy-related hypertensive complications : a systematic review. J Hum Hypertens. 27, 2013, 148-57.
17) Palomba, S. et al. Pregnancy complications in spontaneous and assisted conceptions of women with infertility and subfertility factors : A comprehensive review. Reprod Biomed Online. 33, 2016, 612-28.
18) Giorgione, V. et al. Congenital heart defects in IVF/ICSI pregnancy : systematic review and meta-analysis. Ultrasound Obstet Gynecol. 51, 2018, 33-42.
19) Pelkonen, S. et al. Perinatal outcome of children born after frozen and fresh embryo transfer : the Finnish cohort study 1995-2006. Hum Reprod. 25, 2010, 914-23.
20) Pinborg, A. et al. Large baby syndrome in singletons born after frozen embryo transfer (FET) : is it due to maternal factors or the cryotechnique? Hum Reprod. 29, 2014, 618-27.
21) Wennerholm, UB. et al. Perinatal outcomes of children born after frozen-thawed embryo transfer : a Nordic cohort study from the CoNARTaS group. Hum Reprod. 28, 2013, 2545-53.
22) 杉山隆. ART妊娠による周産期合併症 : 周産期の立場から. 日本産科婦人科学会雑誌. 68, 2016, 3045-51.
23) Jenabi, E. et al. Reasons for elective cesarean section on maternal request : a systematic review. J Matern Fetal Neonatal Med. 2019, 1-6.
24) 今井公俊. 高年初産は難産か? 周産期医学. 44, 2014, 129-32.
25) Thavagnanam, S. et al. A meta-analysis of the association between Caesarean section and childhood asthma. Clin Exp Allergy. 38, 2008, 629-33.
26) Li, HT. et al. The impact of cesarean section on offspring overweight and obesity : a systematic review and meta-analysis. Int J Obes (Lond). 37, 2013, 893-99.
27) Bager, P. et al. Cesarean delivery and risk of intestinal bacterial infection. J Infect Dis. 201, 2010, 898-902.
28) Chen, I. et al. Non-clinical interventions for reducing unnecessary caesarean section. Cochrane Database Syst Rev. 9, 2018, CD005528.
29) Kitamura, T. et al. Multicentre prospective study of perinatal depression in Japan : incidence and correlates of antenatal and postnatal depression. Arch Womens Ment Health. 9, 2006, 121-30.
30) Csatordai, S. et al. Obstetric and sociodemographic risk of vulnerability to postnatal depression. Patient Educ Couns. 67, 2007, 84-92.
31) 池田智明ほか. 生殖と周産期のリエゾン : 生殖医が知っておくべきこと, 産科医ができること. 東京, 診断と治療社, 2020, 165-68.

第2章 母体の管理

P.47 掲載の参考文献
1) Setaro JF. et al. "Pregnancy and cardiovascular disease". Medical complications during pregnancy. Burrow GN. ed. Philadelphia, Elsevier Saunders, 2004, 103-30.
2) Robson SC. et al. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 256, 1989, H1060-5.
3) Mabie WC. et al. A longitudinal study of cardiac output in normal human pregnancy. Am J Obstet Gynecol. 170, 1994, 849-56.
4) Poppas A. et al. Serial assessment of the cardiovascular system in normal pregnancy. Role of arterial compliance and pulsatile arterial load. Circulation. 95, 1997, 2407-15.
5) Clark SL. et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol. 161, 1989, 1439-42.
6) Clapp JF. et al. Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol. 80, 1997, 1469-73.
7) Sadaniantz A. et al. Cardiovascular changes in pregnancy evaluated by two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 5, 1992, 253-8.
8) Child JS. et al. "Management of pregnancy and contraception in congenital heart disease". Congenital heart disease in adults. 3rd ed. Perloff JK, et al. ed. Saunders Elsevier, 2009, 194-220.
9) Hunter S. et al. "Adaptation of the cardiovascular system to pregnancy". Heart disease in pregnancy. Oakley C, ed. BMJ Publishing, 1997, 5-18.
10) 日本循環器学会・日本産科婦人科学会. 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2018年改訂版). 2019, 117p. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_akagi_ikeda.pdf [2021. 10. 18]
11) Connelly MS. et al. Canadian Consensus Conference on Adult Congenital Heart Disease 1996. Can J Cardiol. 14, 1998, 395-452.
12) Siu SC. et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation. 105, 2002, 2179-84.
13) Siu SC. et al. Cardiac Disease in Pregnancy (CARPREG) Investigators. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 104, 2001, 515-21.
14) Silversides CK. et al. Pregnancy Outcomes in Women With Heart Disease : The CARPREG II Study. J Am Coll Cardiol. 71, 2018, 2419-30.
15) Iserin L. Management of pregnancy in women with congenital heart disease. Heart. 85, 2001, 493-4.
16) Canobbio MM. et al. American Heart Association Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Functional Genomics and Translational Biology, Council on Quality of Care and Outcomes Research. Management of Pregnancy in Patients With Complex Congenital Heart Disease : A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 135, 2017, e50-87.
17) Perloff JK. et al. "Pregnancy and congenital heart disease : the mother and the fetus". Congenital Heart Disease in Adults, 2nd ed. Perloff JK, et al. ed. W.B. Saunders, 1998, 144-64.
18) Balci A. et al. ; ZAHARA Investigators. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart. 100, 2014, 1373-81.
19) Chan WS. et al. Anticoagulation of pregnant women with mechanical heart valves : a systematic review of the literature. Arch Intern Med. 160, 2000, 191-6.
20) D'Souza R. et al. Anticoagulation for pregnant women with mechanical heart valves : a systematic review and meta-analysis. Eur Heart J. 38, 2017, 1509-16.
21) Cunningham FG. et al. eds. "Cardiovascular disease". Williams obstetrics. 23rd ed. New York, McGraw-Hill, 2010, 958-82.
22) Simpson LL. Maternal cardiac disease : update for the clinician. Obstet Gynecol. 119, 2012, 345.
23) Montoya ME. et al. Endocarditis during pregnancy. South Med J. 96, 2003, 1156-7.
24) Kebed KY. et al. Pregnancy and postpartum infective endocarditis : a systematic review. Mayo Clin Proc. 89, 2014, 1143-52.
25) Campuzano K. et al. Bacterial endocarditis complicating pregnancy : case report and systematic review of the literature. Arch Gynecol Obstet. 268, 2003, 251-5.
26) Li JM. et al. Frequency and outcome of arrhythmias complicating admission during pregnancy : experience from a highvolume and ethnically-diverse obstetric service. Clin Cardiol. 31, 2008, 538-41.
27) Lavonas EJ. et al. Part 10 : Special Circumstances of Resuscitation : 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 132, 2015, S501-18.
28) 日本妊娠高血圧学会編. "高血圧合併妊娠の管理" 妊娠高血圧症候群 新定義・分類運用上のポイント. 東京, メジカルビュー社, 2019, 67-9.
29) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ309-1 妊婦健診において収縮期血圧 ≧ 140 かつ/または拡張期血圧 ≧ 90mmHgや尿蛋白陽性 (≧1+) を認めたら? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 168-71.
30) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ309-2 妊娠高血圧腎症と診断されたら? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 172-6.
31) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ309-3 妊産褥婦がけいれんを起こしたときの対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 177-80.
32) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ417 分娩時の血圧管理は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 257-9.
P.53 掲載の参考文献
1) 妊産婦死亡症例検討委員会/日本産婦人科医会. 母体安全への提言 2020. vol 11. 2021.
2) 日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン 2021. 2021, 320p.
3) 吉松淳. "周産期の母子神経救急". 脳神経外科診療プラクティス 4 神経救急診療の進め方. 清水宏明編. 東京, 文光堂, 2014, 196-8.
4) Hemphill JC 3rd. et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 46 (7), 2015, 2032-60.
5) Ahmed N. et al. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018. Eur Stroke J. 4 (4), 2019, 307-17.
6) Qureshi AI. et al. Intensive Blood Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 375 (11), 2016, 1033-43.
7) Yoshimatsu J. et al. Factors contributing to mortality and morbidity in pregnancy-associated intracerebral hemorrhage in Japan. J Obstet Gynaecol Res. 40 (5), 2014, 1267-73.
8) Nagaya K. et al. Couse of maternal mortality in Japan. JAMA. 283 (20), 2000, 2661-7.
9) 峰松一夫ほか. 脳卒中レジデントマニュアル. 第2版. 東京, 中外医学社, 2013, 287p.
10) Wardlaw JM. Early signs of brain infarction at CT : observer reliability and outcome after thrombolytic treatment-systematic review. Radiology. 235 (2), 2005, 444-53.
11) 吉松淳. "脳梗塞". 日本の妊産婦を救うために 2015. 関沢明彦ほか編. 東京, 東京医学社, 2015, 253-7.
12) 日本脳卒中学会 脳卒中医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改訂部会. rt-PA (アルテプラーゼ) 静注療法適正治療指針. 第2版. 日本脳卒中学会, 2012.
13) Leonhardt G. et al. Thrombolytic therapy in pregnancy. J Thrombolysis. 21, 2006, 271-6
14) Ahearn GS. et al. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator : a case report and review of treatment options. Arch Intern Med. 162 (11), 2002, 1221-7.
P.58 掲載の参考文献
1) 山田秀人. "特発性血小板減少性紫斑病". 周産期の出血と血栓症 : その基礎と臨床. 第1版. 小林隆夫ほか編. 東京. 金原出版, 2004, 84-91.
2) 宮川義隆ほか. 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨床血液. 55 (8), 2014, 934-47.
3) Gernsheimer T. et al. How I treat thrombocytopenia in pregnancy. Blood. 121 (1),2013, 38-47.
4) Fujimura K. et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 81 (2), 2005, 162-8.
5) Gernsheimer T. et al. Immune thrombocytopenic purpura in pregnancy. Curr Opin Hematol. 14 (5), 2007, 574-80.
6) Kuter DJ. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomized controlled trial. Lancet. 371 (9610), 2008, 395-403.
7) Cheng G. et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE) : a 6-month, randomized, phase 3 study. Lancet. 377 (9763), 2011, 393-402.
8) Provan D. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 115 (2), 2010, 168-86.
9) Scott JR. et al. Fetal platelet counts in the obstetric management of immunologic thrombocytopenic purpura. Am J Obstet Gynecol. 136 (4), 1980, 495-9.
10) Cook RL. et al. Immune thrombocytopenic purpura in pregnancy : a reappraisal of management. Obstet Gynecol. 78 (4), 1991, 578-83.
11) Neunert C. et al. American Society of Hematology : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 117 (16), 2011, 4190-207.
12) British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 120 (4), 2003, 574-96.
13) Duchatel F. et al. Complications of diagnostic ultrasound-guided percutaneous umbilical cord blood sampling : analysis of a series of 341 cases and review of the literature. Eur J Obstet Gynecol Reprod Biol. 52 (2), 1993, 95-104.
14) 川合陽子. 特発性血小板減少性紫斑病と妊娠・出産. Medicina. 33, 1996, 1730-32.
15) Milman N. Iron and pregnancy--a delicate balance. Ann Hematol. 85 (9), 2006, 559-65.
16) 貝原学. 妊婦貧血. 産婦人科治療. 96, 増刊, 2008, 534-8.
17) 森實真由美ほか. 母体疾患の薬物療法, 血液疾患. 周産期医学. 39 (11), 2009, 1545-50.
18) 寺尾俊彦. 血液疾患, 再生不良性貧血. 周産期医学. 24, 増刊号, 1994, 377-9.
19) Killick SB. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 172 (2), 2016, 187-207.
20) 菊地範彦ほか. 血液疾患合併妊娠, 再生不良性貧血. 周産期医学. 41 (8), 2011, 1045-8.
21) Marsh JC. et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 147 (1), 2009, 43-70.
P.64 掲載の参考文献
1) 日本妊娠高血圧学会編. 妊娠高血圧症候群の診療指針 2021. 東京, メジカルビュー社, 2021, 264p.
2) 日本腎臓学会学術委員会編. 腎疾患患者の妊娠 : 診療ガイドライン 2017. 東京, 診断と治療社, 2017, 80p.
3) 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎障害に関する調査研究班. エビデンスに基づくIgA腎症ガイドライン 2020. 東京, 東京医学社, 2020, 88p.
4) 日本腎臓学会編. CKD診療ガイド 2012. 東京, 東京医学社, 2012, 3.
5) 日本腎臓学会. エビデンスに基づくCKD診療ガイドライン 2018. 東京, 東京医学社, 2018, 160p.
6) 日本高血圧学会 高血圧診療ガイド2020作成委員会編. 高血圧診療ガイド 2020. 東京, 文光堂, 2020, 120p.
7) Deshpande NA. et al. Pregnancy outcomes in kidney transplant recipients : a systematic review and meta-analysis. Am J Transplant. 11 (11), 2011, 2388-404.
8) Gorgulu N. et al. Does pregnancy increase graft loss in female renal allograft recipients? Clin Exp Nephrol. 14 (3), 2010, 244-7.
P.67 掲載の参考文献
1) Ko CW. et al. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology. 41 (2), 2005, 359-65.
2) Jelin EB. et al. Management of biliary tract disease during pregnancy : a decision analysis. Surg Endosc. 22 (1), 2008, 54-60.
3) Kuy S. et al. Outcomes following cholecystectomy in pregnant and nonpregnant women. Surgery. 146 (2), 2009, 358-66.
4) Fong ZV. et al. Cholecystectomy During the Third Trimester of Pregnancy : Proceed or Delay? J Am Coll Surg. 228 (4), 2019, 494-502.e1.
5) 胆道閉鎖症研究会. 胆道閉鎖症診療ガイドライン. 東京, へるす出版, 2018, 132p.
6) Fischler B. et al. A population-based study on the incidence and possible pre- and perinatal etiologic risk factors of biliary atresia. J Pediatr. 141 (2), 2002, 217-22.
7) Caton AR. et al. The epidemiology of extrahepatic biliary atresia in New York State, 1983-98. Paediatr Perinat Epidemiol. 18 (2), 2004, 97-105.
8) 日本胆道閉鎖症研究会・胆道閉鎖症全国登録事務局. 胆道閉鎖症全国登録2016年集計結果. 日本小児外科学会雑誌. 54 (2), 2018, 307-13.
9) Sasaki H. et al. Problems during and after pregnancy in female patients with biliary atresia. J Pediatr Surg. 42 (8), 2007, 1329-32.
10) 田原和典ほか. 胆道閉鎖症アップデート : 妊娠と出産. 小児外科. 50, 2018, 75-80.
11) Shimaoka S. et al. Problems during and after pregnancy of former biliary atresia patients treated successfully by the Kasai procedure. J Pediatr Surg. 36 (2), 2001, 349-51.
12) 日本妊娠高血圧学会編. "腎移植患者の妊娠と管理は? " 妊娠高血圧症候群の診療指針 2015 Best Practice Guide. 東京, メジカルビュー社, 2015, 132-3.
13) Kubo S. et al. Pregnancy outcomes after living donor liver transplantation : results from a Japanese survey. Liver Transpl. 20 (5), 2014, 576-83.
14) Deshpande NA. et al. Pregnancy outcomes of liver transplant recipients : a systematic review and meta-analysis. Liver Transpl. 18 (6), 2012, 621-9.
15) Zullo F. et al. Pregnancy after liver transplantation : a case series and review of the literature. J Matern Fetal Neonatal Med. 34 (19), 2021, 3269-76.
P.74 掲載の参考文献
1) van der Woude CJ. et al. The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. journal of Crohn's and Colitis. 9 (2), 2015, 107-24.
2) Hendy P. et al. IBD : reproductive health, pregnancy and lactation. Frontline Gastroenterology. 6 (1), 2015, 38-43.
3) Uma Mahadevan. et al. Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients with Inflammatory Bowel Disease Clin Gastroenterol Hepatol. 11 (3), 2013, 286-e24.
4) Beaulieu DB. et al. Inflammatory bowel disease in pregnancy. World J Gastroenterol.17 (22), 2011, 2696-701.
5) Manosa M. et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease : a large cohort survey. Scand J Gastroenterol.48 (4), 2013, 427-32.
6) Dominitz JA. et al. Outcomes of infants born to mothers with inflammatory bowel disease : a population based cohort study. Am J Gastroenterol. 97 (3), 2002, 641-8.
7) Longstreth GF. et al. Functional bowel disorders. Gastroenterology. 130 (5), 2006, 1480-91.
8) Augustin G. et al. Non-obstetrical acute abdomen during pregnancy. Eur J Obstet Gynecol Reprod Biol.131 (1), 2007, 4-12.
9) Pedrosa I. et al. Pregnant patients suspected of having acute appendicitis : effect of MR imaging on negative laparotomy rate and appendiceal perforation rate. Radiology. 250 (3), 2009, 749-57.
10) Yilmaz. HG. et al. Acute appendicitis in pregnancy : new information that contradicts long-held clinical beliefs. Am J Obstet Gynecol. 182 (5), 2000, 1027-9.
11) Prodromidou A. et al. Outcomes after open and laparoscopic appendectomy during pregnancy : A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 225, 2018, 40-50.
12) Parangi S. et al. Surgical gastrointestinal disorders during pregnancy. Am J Surg. 193 (2), 2007, 223-32.
13) McGee TM. Acute appendicitis in pregnancy. Aust N Z J Obstet Gynaecol. 29 (4), 1989, 378-85.
14) Yilmaz HG. et al. Acute appendicitis in pregnancy--risk factors associated with principal outcomes : a case control study. Int J Surg. 5 (3), 2007, 192-7.
P.78 掲載の参考文献
1) 厚生労働省. 平成15年保健福祉動向調査 : アレルギー様症状.
2) Jolving R. et al. Prevalence of maternal chronic diseases during pregnancy-a nationwide population based study from 1989 to 2013. Acta Obstet Gynaecol Scand. 95, 2016, 1295-304.
3) Bonham CA. et al. Asthma Outcomes and Management During Pregnancy. Chest. 153, 2018, 515-27.
4) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会. 喘息予防・管理ガイドライン 2018. (Japanese Edition). Kindle版.
P.84 掲載の参考文献
1) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病. 55, 2012, 485-504.
2) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ005-2 妊娠糖尿病 (GDM), 妊娠中の明らかな糖尿病, ならびに糖尿病 (DM) 合併妊婦の管理・分娩は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 25-8.
3) 日本糖尿病学会. "妊婦の糖代謝異常". 糖尿病診療ガイドライン 2019. 東京, 南江堂, 2019, 283-304.
4) 末原節代ほか. 当センターにおける糖代謝異常妊婦の頻度と先天異常に関する検討. 糖尿病と妊娠. 10, 2010, 104-8.
5) National Institute for Health and Care Excellence Guideline. Diabetes in pregnancy : management from preconception to the postnatal period. 2020. https://www.nice.org.uk/guidance/ng3/ [ 2021. 9. 30]
6) American Diabetes Association. Management of Diabetes in Pregnancy : Standards of medical care in diabetes-2020. Diabetes Care. 43 (Suppl 1), 2020, S183-92.
P.91 掲載の参考文献
1) Stagnaro-Green A. et al. The American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid. 21, 2011, 1081-125.
2) Alexander EK. et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 27, 2017, 315-89.
3) 日本甲状腺学会編. "FCQ1. 妊娠初期における薬物治療は, 第一選択薬として何が推奨されるか? ". バセドウ病治療ガイドライン 2019. 東京, 南江堂, 2049, 2-6.
4) Practice bulletin No. 148 : Thyroid Disease in Pregnancy. Obstet Gynecol. 125 (4), 2015, 996-1005.
5) Mestman JH. "Thyroid and parathyroid diseases in pregnancy". Obstetrics : Normal and Problem Pregnancies 7th ed. Gabbe S, et al eds. Philadelphia, Elsevier, 2017, 910-37,
6) Cunningham FG. et al. eds. "Chapter 58 : Endocrine diseases". Williams Obstetrics 25th ed. New York, McGraw-Hill Medical, 2018, 1118-37.
7) Millar LK. et al. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol. 84, 1994, 946-9.
8) Luton D. et al. Management of Graves' disease during pregnancy : the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab. 90, 2005, 6093.
9) Patil-Sisodia K. et al. Graves hyperthyroidism and pregnancy : a clinical update. Endocr Pract. 16, 2010, 118-29.
10) Ross DS. Hyperthyroidism during pregnancy : Treatment. Cooper DS. et al eds. UpToDate Topic 7884 Version 24.0, Apr 20, 2020. www.uptodate.com [2021. 9. 30]
11) Ross DS. Overview of thyroid disease and pregnancy. Cooper DS. et al eds, UpToDate Topic 7868 Version 17.0, Apr 20, 2020. www.uptodate.com [2021. 9. 30]
12) Haddow JE. et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 341, 1999, 549-55.
13) Henrichs J. et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood : the generation R study. J Clin Endocrinol Metab. 95, 2010, 4227-34.
14) Smit BJ. et al. Neurologic development of the newborn and young child in relation to maternal thyroid function. Acta Paediatr. 89 (3), 2000, 291-5.
15) 中村浩淑. 甲状腺結節取り扱い診療ガイドライン. 日本甲状腺学会誌. 1, 2010, 91-5.
16) Uruno T. et al. Optimal timing of surgery for differentiated thyroid cancer in pregnant women. World J Surg. 38, 2014, 704-8.
P.97 掲載の参考文献
1) 橋本博史. "SLEの概念とその変遷". 全身性エリテマトーデス臨床マニュアル. 東京, 日本医事新報社, 2006, 2-7.
2) Aringer M. et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 71 (9), 2019, 1400-12. Ann Rheum Dis. 78 (9), 2019, 1151-9.
3) Anami A. et al. The predictive value of anti-SS-A antibodies titration in pregnant women with fetal congenital heart block. Mod Rheumatol. 23 (4), 2013, 653-8.
4) Miyakis S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 4, 2006, 295-306.
5) Ogishima D. et al. Placental pathology in systemic lupus erythematosus with antiphospholipid antibodies. Pathology International. 50, 2000, 224-9.
6) 日本産科婦人科学会/日本産婦人科医会編集・監修. "CQ104-2 添付文書上いわゆる禁忌の医薬品のうち, 特定の状況下では妊娠中であってもインフォームドコンセントを得たうえで使用される代表的医薬品は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 64-6.
7) Parke A. et al. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol. 23 (10), 1996, 1715-8.
8) Nakamura Y. et al. Immnunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphosopholipid antibodies. Am J Reprod Immunol. 41, 1999, 307-11.
9) Buyon JP. et al. Neonatal lupus : Review of proposed pathogenesis and clinical data from US-based research resistry for neonatal lupus. Autoimmunity. 36, 2003, 41-50.
10) De Carolis S. et al. Autoimmune Congenital Heart Block : A Review of Biomarkers and Management of Pregnancy. Front Pediatr. 8, 2020, 607515.
P.101 掲載の参考文献
1) Thomas CL. et al. Psychosis after childbirth : Ecological aspects of a single impact stress. Am J Med Sci. 238, 1963, 363-88.
2) 宗田聡. これからはじめる周産期メンタルヘルス. 東京, 南山堂, 2017, 80p.
3) 岡崎祐士ほか. 精神障害者の妊娠と出産 : 分裂病について. 周産期医学. 4, 1974, 921-34.
4) 佐川正ほか. "精神疾患". 合併症妊娠. 改訂第3版, 村田雄二編. 大阪, メディカ出版, 2014, 359-70.
5) 荒木勤. 最新産科学 : 異常編. 改訂第5版. 東京, 文光堂, 2005, 254.
6) 本多裕ほか. 妊娠・産褥期の精神障害. 臨床精神医学. 10, 1981, 21-8.
7) 「てんかん診療ガイドライン」作成委員会編. てんかん診療ガイドライン 2018. 日本神経学会監修. 東京, 医学書院, 2018, 240p.
8) 日本周産期メンタルヘルス学会. 周産期メンタルヘルスコンセンサスガイド. 初版. 2017, 120
9) Kuemmerle HP. et al. Clinical Pharmacology in Pregnancy. New York, Thieme-Stratton, 1984.
P.109 掲載の参考文献
1) 日本婦人科腫瘍学会編. "妊娠合併子宮頸癌の治療". 子宮頸癌治療ガイドライン 2017年版. 金原出版, 東京, 2017, 168-77.
2) Shivvers SA. et al. Preinvasive and invasive breast and cervical cancer prior to or during pregnancy. Clin Perinatol. 24, 1997, 369-89.
3) ACOG Practice Bulletin No.140. management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol. 122, 2013, 1338-67.
4) 日本産科婦人科学会・日本産婦人科医会編集・監修, "CQ502 妊娠中の子宮頸部細胞診がNILM以外の場合の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 2020, 281-3.
5) Hannigan EV. et al. Cone biopsy during pregnancy. Obstet Gynecol. 60, 1982, 450-5.
6) Kyrgiou M. et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions : systematic review and meta-analysis. Lancet. 367, 2006, 489-98.
7) Yoonessi M. et al. Cervical intra-epithelial neoplasm in pregnancy. Int J Gynaecol Obstet. 20, 1982, 111-8.
8) Kirkup W. et al. Colposcopy in the management of the pregnant patient with abnormal cervical cytology. Br J Obstet Gynaecol. 87, 1980, 322-5.
9) Lacour RA. et al. Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol. 192, 2005, 1449-51.
10) 佐藤章ほか. "悪性卵巣腫瘍・子宮頸癌". 合併症妊娠. 改訂3版. 村田雄二編. 大阪, メディカ出版, 2011, 341-58.
11) Sood AK. et al. Surgical management of cervical cancer complicating pregnancy : a case-control study. Gynecol Oncol. 63, 1996, 294-8.
12) 日本産科婦人科学会・日本産婦人科医会編集・監修, "CQ504 妊娠中に発見された付属器腫瘤の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 2020, 286-7.
13) Jacob JH. et al. Diagnosis and management of cancer during pregnancy. Semin Perinatol. 14, 1990, 79-87.
14) Horowitz NS. Management of adnexal masses in pregnancy. Clin Obstet Gynecol. 54, 2011, 519-27.
15) Chen MM. et al. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 112, 2008, 333-40.
16) 小澤真帆. 卵巣腫瘍合併妊娠. 産科診療トラブルシューティング. 東京, 金原出版, 2005, 273-87.
17) 日本産科婦人科学会・日本産婦人科医会編集・監修, "CQ504 妊娠中に発見された付属器腫瘤の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 2020, 286-7.
18) Cagino L. et al. Surgical management of adnexal mass in pregnancy : a systematic review and meta-analysis. J Minim Invasive Gynecol. 28, 2021, 1171-82.
19) Lev-Toaff AS. et al. Leiomyomas in pregnancy : sonographic study. Radiology. 164, 1987, 375-80.
20) Vitagliano A. et al. Uterine fibroid size modifications during pregnancy and puerperium : evidence from the first systematic review of literature. Arch Gynecol Obstet. 297, 2018, 823-35.
21) Rice JP. et al. The clinical significance of uterine leiomyomas in pregnancy. Am J Obstet Gynecol. 160, 1989, 1212-6.
22) 日本産科婦人科学会・日本病理学会編. "絨毛性疾患の臨床". 絨毛性疾患取扱い規約. 第3版. 東京, 金原出版, 2011, 33-42.
23) 松井英雄ほか. 絨毛性疾患. 周産期医学必修知識. 第8版. 周産期医学. 46, 2016, 226-8.
24) Tsakiridis I. et al. Diagnosis and Management of Gestational Trophoblastic Disease : A Comparative Review of National and International Guidelines. Obstet Gynecol Surv. 75, 2020, 747-56.
P.114 掲載の参考文献
1) 日本乳癌学会編. 日本乳癌学会による患者さんのための乳癌診療ガイドライン 2019年版 第6版. 東京, 金原出版, 2019, 240p.
2) 日本がん・生殖医学会編. 乳がん患者の妊娠・出産と生殖医療に関する診療の手引き 2017年版 第2版. 東京, 金原出版, 2017, 212p.
3) Sanz MA. et al. Management of acute promyelocytic leukemia : updated recommendations from an expert panel of the European LeukemiaNet. Blood. 133 (15), 2019, 1630-43.
4) Cardonick E. Pregnancy-associated breast cancer : optimal treatment options. Int J Womens Health. 6, 2014, 935-43.
5) Ali S. et al. : British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol. 170 (4), 2015, 487-95.
6) 日本血液学会. 造血器腫瘍診療ガイドライン 2018年版 補訂版 [2020年4月] 東京, 金原出版, 2020, 428p.
P.119 掲載の参考文献
1) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ010 妊娠前の体格や妊娠中の体重増加量については? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 45-8.
2) Marlene M. et al. "Preconceptional Counseling". Williams Obstetrics. 24th ed. New York, McGraw-Hill, 2014. (Kindle version).
3) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ204 反復・習慣流産患者の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 119-25.
4) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ308 常位胎盤早期剥離 (早剥) の診断・管理は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 164-7.
5) 妊娠高血圧学会編. "CQ 産褥期の薬物療法と授乳は? ". 妊娠高血圧症候群の診療指針 2015. 東京, メジカルビュー社, 2015, 235.
6) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ309-2 妊娠高血圧症候群と診断されたら? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 172-6.
7) Vajda FJ. Treatment options for pregnant women with epilepsy. Expert Opin Pharmacother. 9 (11), 2008, 1859-68.
8) Jeha LE. et al. Optimizing outcomes in pregnant women with epilepsy. Cleve Clin J Med. 72 (10), 2005, 938-40, 942-5.
9) 日本腎臓学会編. CKD診療ガイド 2012. 東京, 東京医学社, 2012, 3.
10) Wilson RD. et al. SOGC CLINICAL PRACTICE GUIDELINE : Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies. J Obstet Gynaecol Can. 37 (6), 2015, 534-49.
国立国際医療研究センター. 糖尿病情報センター. http://dmic.ncgm.go.jp/general/about-dm/080/030/13.html [2020.5.22]
「てんかん診療ガイドライン」作成委員会編. "てんかんと女性". てんかん診療ガイドライン 2018. 日本神経学会監修. 2018. 133-43. https://www.neurology-jp.org/guidelinem/epgl/tenkan_2018_13.pdf [2021.12.12]
日本循環器学会/日本産科婦人科学会合同ガイドライン. 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_akagi_ikeda.pdf [2020.5.22]
日本腎臓学会編. 腎疾患患者の妊娠 : 診療ガイドライン 2017. https://cdn.jsn.or.jp/data/jsn-pregnancy.pdf [2020.5.22]
日本リウマチ学会編. 関節リウマチ診療ガイドライン 2014. https://minds.jcqhc.or.jp/n/med/4/med0064/G0000706/0053/0059 [2020.5.22]
全国遺伝子医療部門連絡会議. http://www.idenshiiryoubumon.org/ [2020.5.22]
平成30年 (2018年) 3月厚生労働科学研究費補助金 難治性疾患等政策研究事業. 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班. 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針【医師用CQ】. https://ra-ibd-sle-pregnancy.org/doctor_toward/images/ishiyousshisin.pdf [2021.12.12]
P.126 掲載の参考文献
1) Romero R. et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence : prevalence and clinical significance. Am J Obstet Gynecol. 167, 1992, 1086-91.
2) Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicentre randomised trial of cervical cerclage. MRC/RCOG Working Party on Cervical Cerclage. Br J Obstet Gynaecol. 100, 1993, 516-23.
3) Oh KJ. et al. Evidence that antibiotic administration is effective in the treatment of a subset of patients with intra-amniotic infection/inflammation presenting with cervical insufficiency. Am J Obstet Gynecol. 221, 2019, 140 e1-e18.
4) Brown JA. et al. History- or ultrasound-based cerclage placement and adverse perinatal outcomes. J Reprod Med. 56, 2011, 385-92.
5) Berghella V, Mackeen AD. Cervical length screening with ultrasound-indicated cerclage compared with history-indicated cerclage for prevention of preterm birth : a meta-analysis. Obstet Gynecol. 118, 2011, 148-55.
6) Berghella V. et al. Cerclage for sonographic short cervix in singleton gestations without prior spontaneous preterm birth : systematic review and meta-analysis of randomized controlled trials using individual patient-level data. Ultrasound Obstet Gynecol. 50, 2017, 569-77.
7) Berghella V. et al. Effectiveness of cerclage according to severity of cervical length shortening : a meta-analysis. Ultrasound Obstet Gynecol. 35, 2010, 468-73.
8) Berghella V. et al. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth : a meta-analysis. Obstet Gynecol. 117, 2011, 663-71.
9) Ehsanipoor RM. et al. Physical Examination-Indicated Cerclage : A Systematic Review and Meta-analysis. Obstet Gynecol. 126, 2015, 125-35.
10) 大槻克文. 22, 23週【妊娠時期別にみた分娩の対応-どうすれば児の予後を改善できるか?】22, 23週 母体・胎児 治療困難例 (胎胞膨隆, CAOSなど) への対応. 周産期医学. 46, 2016, 829-33.
11) Schuit E. et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies : an individual participant data meta-analysis. BJOG. 122, 2015, 27-37.
12) Suhag A. et al. Prior Ultrasound-Indicated Cerclage : Comparison of Cervical Length Screening or History-Indicated Cerclage in the Next Pregnancy. Obstet Gynecol. 126, 2015, 962-8.
13) Ammon Avalos L. et al. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol. 94, 2012, 417-23.
14) Cunningham FG. et al. Williams Obstetrics. 25th ed ed : McGraw-Hill Education ; 2018. xvi, 1328 p.
15) Kajii T. et al. Anatomic and chromosomal anomalies in 639 spontaneous abortuses. Hum Genet. 55, 1980, 87-98.
16) Lawson CC. et al. Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol. 206, 2012, 327 e1-8.
17) Boivin JF. Risk of spontaneous abortion in women occupationally exposed to anaesthetic gases : a meta-analysis. Occup Environ Med. 54, 1997, 541-8.
18) 長谷川ゆりほか. 治療困難症例から学ぶ 後期流産の原因と次回妊娠への対策. 日本周産期・新生児医学会雑誌. 50, 2014, 139-40.
19) 加藤慧ほか. 妊娠初期の頸管ポリープと, 後期流産及び早産との関連について. 日本周産期・新生児医学会雑誌. 55, 2019, 11-6.
20) Elliott JP. et al. Chronic abruption-oligohydramnios sequence. J Reprod Med. 43, 1998, 418-22.
21) Morita A. et al. Therapeutic amnioinfusion for chronic abruption-oligohydramnios sequence : a possible prevention of the infant respiratory disease. J Obstet Gynaecol Res. 40, 2014, 1118-23.
22) Richter J. et al. Amniopatch procedure after previable iatrogenic rupture of the membranes : a two-center review. Prenat Diagn. 33, 2013, 391-6.
23) Meites E. et al. C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med. 363, 2010, 1382-3.
P.131 掲載の参考文献
1) 日本産科婦人科学会編集. 産科婦人科用語集・用語解説集 改定第4版. 東京, 金原出版, 2018.
2) Celik C. et al. Methotrexate for cervical pregnancy. A case report. J Reprod Med. 48, 2003, 130-2.
3) Abusheikha N. et al. Extra-uterine pregnancy following assisted conception treatment. Hum Reprod Update. 6, 2000, 80-92.
4) Ash A. et al. Caesarean scar pregnancy. BJOG. 114, 2007, 253-63.
5) Timor-Tritsch, IE. et al. Cesarean scar pregnancy. Diagnosis and pathogenesis. Obstet Gynecol Clin N Am. 46, 2019, 797-811.
6) Jayaram P. et al. Expectant management of caesarean scar ectopic pregnancy : a systematic review. J Perinat Med. 46, 2018, 365-72.
7) Cali G. et al. Outcome of cesarean scar pregnancy managed expectantly : systematic review and meta-analysis. Ultrasound Obstet Gynecol. 51, 2018, 169-75.
8) Jeng CJ. et al. Transvaginal ultrasound-guided treatment of cervical pregnancy. Obstet Gynecol. 109, 2007, 1076-82.
9) Rotas MA. et al. Cesarean scar ectopic pregnancies : etiology, diagnosis, and management. Obstet Gynecol. 107, 2006, 1373-81.
10) Murji A. et al. Conservative Management of Cervical Ectopic Pregnancy. J Obstet Gynaecol Can. 37, 2015, 1016-20.
11) Jurkovicm D. et al. Surgical treatment of Cesarean scar ectopic pregnancy : efficacy and safety of ultrasound-guided suction curettage. Ultrasound Obstet Gynecol. 47, 2016, 511-7.
12) Ushakov FB. et al. Cervical pregnancy : past and future. Obstet Gynecol Surv. 52, 1997, 45-59.
13) Hofmann HM. et al. Cervical pregnancy : case reports and current concepts in diagnosis and treatment. Arch Gynecol Obstet. 241, 1987, 63-9.
14) Jurkovic D. et al. Diagnosis and treatment of early cervical pregnancy : A review and a report of two cases treated conservatively. Ultrasound Obstet Gynecol. 8, 1996, 373-80.
15) David MP. et al. Cervico-isthmic pregnancy carried to term. Obstet Gynecol. 56, 1980, 247-52.
16) Godin PA. et al. An ectopic pregnancy developing in a previous caesarian section scar. Fertil Steril. 67, 1997, 398-400.
17) Sekiguchi A. et al. Ultrasound Detection of Lacunae-like Image of a Cesarean Scar Pregnancy in the First Trimester. Journal of Nippon Medical School. 80, 2013, 70-3.
18) Vial Y. et al. Pregnancy in a cesarean scar. Ultrasound Obstet Gynecol. 16, 2000, 592-3.
19) Cali G. et al. First-trimester prediction of surgical outcome in abnormally invasive placenta using the cross-over sign. Ultrasound Obstet Gynecol. 51, 2018, 184-8.
20) Cali G. et al. Natural history of Cesarean scar pregnancy on prenatal ultrasound : the crossover sign. Ultrasound Obstet Gynecol. 50, 2017, 100-4.
21) Society for Maternal-Fetal Medicine, Miller, R. et al. Society for Maternal-Fetal Medicine (SMFM) consult series #49 : Cesarean scar pregnancy. Am J Obstet Gynecol. 222, 2020, B2-14
22) Timor-Trtisch IE. et al. A new minimally invasive treatment for cesarean scar pregnancy and cervical pregnancy. Am J Obstet Gynecol. 215, 2016, 351.e1-8.
23) Tanos V. et al. Hysteroscopic management of cervical pregnancy : Case series and review of the literature. J Gynecol Obstet Hum Reprod. 48, 2019, 247-53.
24) He Y. et al. Combined laparoscopy and hysteroscopy vs. uterine curettage in the uterine artery embolization-based management of cesarean scar pregnancy : a retrospective cohort study. BMC Women's Health. 14, 2014, 116.
25) Hung TH. et al. Prognostic factors for an unsatisfactory primary methotrexate treatment of cervical pregnancy : A quantitative review. Human Reprod. 13, 1998, 2636-42.
26) Maheux-Lacroix S. et al. Cesarean scar pregnancies : A systematic review of treatment options. J Minim Invasive Gynecol. 24, 2017, 915-25.
P.140 掲載の参考文献
1) American College of Obstetricians and Gynecologists ; Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin No. 127 : Management of preterm labor. Obstet Gynecol. 119, 2012, 1308-17.
2) Shiozaki A. et al. Multiple pregnancy, short cervix, part-time worker, steroid use, low educational level and male fetus are risk factors for preterm birth in Japan : a multicenter, prospective study. J Obstet Gynaecol Res.40, 2014, 53-61.
3) Andrews WW. et al. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstet Gynecol.101, 2003, 847-55.
4) Committee on Practice Bulletins-Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin No. 130 : prediction and prevention of preterm birth. Obstet Gynecol.120, 2012, 964-73.
5) Yada Y. et al. Synergic interaction between ritodrine and magnesium sulfate on the occurrence of critical neonatal hyperkalemia : A Japanese nationwide retrospective cohort study. Sci Rep.10, 2020, 7804.
6) Gyamfi-Bannerman C. et al. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med.374, 2016, 1311-20.
7) Committee on Obstetric Practice. Committee Opinion No. 713 : Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol.130, 2017, e102-9.
8) Ogawa M. et al. Ritodrine should be carefully administered during antenatal glucocorticoid therapy even in nondiabetic pregnancies. ISRN Obstet Gynecol. 2013, 2013, 120735.
9) Doyle LW. et al. Antenatal magnesium sulfate and neurologic outcome in preterm infants : a systematic review. Obstet Gynecol. 113, 2009, 1327-33.
10) 高木耕一郎. 妊娠中毒症 : どのように変わったか 幸帽児帝王切開法. 臨床婦人科産科. 51, 1997, 305-7.
11) Thomas SJ. et al. The risk of periventricular-intraventricular hemorrhage with vacuum extraction of neonates weighing 2000 grams or less. J Perinatol. 17, 1997, 37-41.
12) 松田義雄ほか. 切迫早産の処置と治療 : 陣痛の抑制. 産科と婦人科. 64, 1997, 327-32.
13) Middleton P. et al. Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more). Cochrane Database Syst Rev. 1, 2017.
14) Wojcieszek, AM. et al. Antibiotics for prelabour rupture of membranes at or near term. Cochrane Database Syst Rev. (10), 2014.
15) Tajik P. et al. Using vaginal Group B Streptococcus colonisation in women with preterm premature rupture of membranes to guide the decision for immediate delivery : a secondary analysis of the PPROMEXIL trials. BJOG. 121, 2014, 1263-72.
16) Lencki SG. et al. Maternal and umbilical cord serum interleukin levels in preterm labor with clinical chorioamnionitis. Am J Obstet Gynecol. 170, 1994, 1345-51.
17) Bond DM. et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database Syst Rev. 3, 2017.
18) ACOG Practice Bulletin No. 188. Prelabor rupture of membranes. Obstet Gynecol. 131, 2018, e1-14.
19) Kenyon S. et al. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. (12), 2013.
P.145 掲載の参考文献
1) 日本産科婦人科学会/日本産婦人科医会編集・監修. 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 25-8. "CQ005-2 妊娠糖尿病 (GDM), 妊娠中の明らかな糖尿病, ならびに糖尿病 (DM) 合併妊婦の管理・分娩は? ".
2) Leanne Bellamy, et al. Type 2 diabetes mellitus after gestational diabetes : a systematic review and meta-analysis. Lancet. 373, 2009, 1773-9.
3) 日本糖尿病・妊娠学会編. 妊婦の糖代謝異常 診療・管理マニュアル. 改訂第2版. 東京, メジカルビュー社, 2018.
4) 日本産科婦人科学会/日本産婦人科医会編集・監修. "CQ005-1 妊婦の糖代謝異常スクリーニングと診断のための検査は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 22-4.
5) 日本産科婦人科学会/日本産婦人科医会編集・監修. "CQ310 巨大児 (出生体重4,000g 以上) が疑われる妊婦への対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 181-5.
P.151 掲載の参考文献
1) Roberts JM. Gammill HS. Preeclampsia Recent insights. Hypertension. 46, 2005, 1243-9.
2) Wang A. et al. Preeclampsia : The role of angiogenic factors in its pathogenesis. Physiology. 24, 2009, 147-58.
3) Caniggia I. et al. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest. 103, 1999, 1641-50.
4) Ahmad S. et al. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc Cell. 13, 2011, 15.
5) 日本妊娠高血圧学会編. 妊娠高血圧症候群 新定義・分類 : 運用上のポイント. 東京, メジカルビュー, 2019, 8-15.
6) Mikami Y. et al. Provisional criteria for the diagnosis of hypertension in pregnancy using home blood pressure measurements. Hypertens Res. 40, 2017, 679-84.
7) 日本妊娠高血圧学会編. 妊娠高血圧症候群の診療指針 2015. 東京, メジカルビュー, 2015, 42-7.
8) Gant NF. et al. A study of angiotensin II pressor response throughout promigravid pregnancy. J Clin Invest. 52, 1973, 2682-9.
9) Zeisler H. et al. Predictive value of the sFlt-1 : PlGF ratio in women with suspected preeclampsia. N Engl J Med. 374, 2016, 13-22.
10) Bian X. et al. Short-terrm prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1) /PlGF (placental growth factor) ratio in asian women with suspected preeclampsia. Hypertension. 74, 2019, 164-72.
11) 日本産科婦人科学会/日本産婦人科医会編集・監修. "CQ309-2 妊娠高血圧症候群と診断されたら? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 172-6.
12) 日本妊娠高血圧学会編. 妊娠高血圧症候群の診療指針 2015. 東京, メジカルビュー, 2015, 94-101.
13) Seki H. Long-term treatment with nicardipine for severe pre-eclampsia. Int J Gynaecol. Obstet. 76, 2002, 135-41.
14) Cooper WO. et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J. Med. 354, 2006, 2443-51.
15) Sekine T, Endou H. Children's toxicology from bench to bed--Drug-induced renal injury (3) : Drug transporters and toxic nephropathy in childhood. J. Toxicol. Sci. 34, 2009, SP259-65.
16) Pritchard JA. et al. Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med. 250, 1954, 89-98.
17) Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count : a severe consequence of hypertension in pregnancy. 1982. Am J Obstet Gynecol. 142, 1982, 159-67.
18) Martin JN Jr. et al. Understanding and managing HELLP syndrome : the integral role of aggressive glucocorticoids for mother and child. Am. J Obstet Gynecol. 195, 2006, 914-34.
19) Jayawardena L, McNamara E. Diagnosis and management of pregnancies complicated by haemolysis, elevated liver enzymes and low platelets syndrome in the tertiary setting. Intern Med J. 50, 2020. 342-9.
20) Geary M. The HELLP syndrome. Br J Obstet Gynaecol. 104, 1997, 887-91.
21) Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 103, 2004, 981-91.
22) Sibai BM. et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 169, 1993, 1000-6.
23) Gul A. et al. Perinatal outcome in severe preeclampsia-eclampsia with and without HELLP syndrome. Gynecol Obstet Invest. 59, 2005, 113-8.
24) Ertan AK. et al. Clinical and biophysical aspects of HELLP-syndrome. J Perinat Med. 30, 2002, 483-9.
25) Koenen SV. et al. Is there a diurnal pattern in the clinical symptoms of HELLP syndrome?. J Matern. Fetal Neonatal Med. 19, 2006, 93-9.
26) Mao M, Chen C. Corticosteroid therapy for management of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome : A meta-analysis. Med. Sci. Monit. 21, 2015, 3777-83.
27) 日本産科婦人科学会/日本産婦人科医会編集・監修. "CQ312 妊産褥婦にHELLP 症候群・臨床的急性妊娠脂肪肝を疑ったら? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 189-92.
P.157 掲載の参考文献
1) 日本産科婦人科学会編集. 産科婦人科用語集・用語解説集. 改定第4版. 東京, 日本産科婦人科学会, 2017.
2) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ304 前置胎盤の診断・管理は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 147-50.
3) Silver RM. Abnormal Placentation : Placenta Previa, Vasa Previa, and Placenta Accreta. Obstet Gynecol. 126 (3), 2015, 654-68.
4) Jauniaux E. et al. Placenta accreta spectrum : pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 218 (1), 2018, 75-87.
5) Jauniaux E. et al. FIGO consensus guidelines on placenta accreta spectrum disorders : Epidemiology. Int J Gynaecol Obstet. 140 (3), 2018, 265-73.
6) Shukunami K. et al. A small-angled thin edge of the placenta predicts abnormal placentation at delivery. J Ultrasound Med. 24 (3), 2005, 331-5.
7) Vintzileos AM. et al. Using ultrasound in the clinical management of placental implantation abnormalities. Am J Obstet Gynecol. 213 (4 Suppl), 2015, S70-7.
8) Collins SL. et al. Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet Gynecol. 47 (3), 2016, 271-5.
9) D'Antonio F. et al. Prenatal identification of invasive placentation using magnetic resonance imaging : systematic review and meta-analysis. Ultrasound Obstet Gynecol. 44 (1), 2014, 8-16.
10) Ward CR. Avoiding an incision through the anterior previa at cesarean delivery. Obstet Gynecol. 102 (3), 2003, 552-4.
11) Kotsuji F. et al. Transverse uterine fundal incision for placenta praevia with accreta, involving the entire anterior uterine wall : a case series. BJOG. 120 (9), 2013, 1144-9.
12) Fujiwara-Arikura S. et al. Re : Transverse uterine fundal incision for placenta praevia with accreta, involving the entire anterior uterine wall : a case series. Spontaneous uterine rupture during the subsequent pregnancy after transverse uterine fundal incision for placenta praevia with accreta. BJOG. 125 (3), 2018, 389-90.
13) 吉田好雄ほか編. 帝王切開の強化書 Kaiserを極める. 東京, 金原出版, 2017, 66p.
14) 小西郁生編. OGS NOW 9 前置胎盤・前置癒着胎盤の手術. 東京, メジカルビュー社, 2012, 82-93.
15) Yamashita Y. et al. Transcatheter arterial embolization of obstetric and gynaecological bleeding : efficacy and clinical outcome. Br J Radiol. 67 (798), 1994, 530-4.
16) Ono Y. et al. Study of the utility and problems of common iliac artery balloon occlusion for placenta previa with accreta. J Obstet Gynaecol Res. 44 (3), 2018, 456-62.
17) Chen L. et al. Clinical evaluation of prophylactic abdominal aortic balloon occlusion in patients with placenta accreta : a systematic review and meta-analysis. BMC Pregnancy Childbirth. 19 (1), 2019, 30p.
18) Sentilhes L. et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 115 (3), 2010, 526-34.
19) Miyakoshi K. et al. Retrospective multicenter study of leaving the placenta in situ for patients with placenta previa on a cesarean scar. Int J Gynaecol Obstet. 140 (3), 2018, 345-51.
20) 日本インターベンショナルラジオロジー学会. 産科危機的出血に対するIVR施行医のためのガイドライン 2017. http://www.jsir.or.jp/about/guide_line/sanka/
P.162 掲載の参考文献
1) Matsuda Y. et al. Impact of maternal age on the incidence of obstetrical complications in Japan. J Obstet Gynaecol Res. 37 (10), 2011, 1409-14.
2) 竹田省. 常位胎盤早期剥離. 産科と婦人科. 11, 1998, 1506-9.
3) 公益財団法人日本医療機能評価機構産科医療補償制度再発防止委員会. 第10回産科医療補償制度再発防止に関する報告書 : 産科医療の質の向上に向けて. http://www.sanka-hp.jcqhc.or.jp/documents/prevention/report/pdf/Saihatsu_Report_10_All.pdf
4) Page EW. et al. Abruptio placentae : Dangers of delay in delivery. Obstet Gynecol. 3, 1954, 385-93.
5) 公益財団法人日本医療機能評価機構産科医療補償制度再発防止委員会. 第2回産科医療補償制度再発防止に関する報告書 : 産科医療の質の向上に向けて. http://www.sanka-hp.jcqhc.or.jp/documents/prevention/report/pdf/Saihatsu_Report_02_All.pdf
6) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ308 常位胎盤早期剥離 (早剥) の診断・管理は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 164-7.
7) Gluck O. et al. Bloody amniotic fluid during labor : Prevalence, and association with placental abruption, neonatal morbidity, and adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 234, 2019, 103-7.
8) Jaffe MH. et al. Sonography of abruptio placentae. AJR Am J Roentgenol. 137, 1981, 1049-54.
9) 川名有紀子ほか. 子宮内胎児死亡を伴う常位胎盤早期剥離症例の分娩様式から見た予後の検討. 日本周産期・新生児医学会誌. 48, 2012, 22-6.
10) 山本智子. "常位胎盤早期剥離". 産科周術期管理のすべて. 木下勝之, 竹田省編. 東京, メジカルビュー社, 2005, 334-8.
11) Takeda S. et al. A minimally invasive hemostatic strategy in obstetrics aiming to preserve uterine function and enhance the safety of subsequent pregnancies. Hypertens Res Pregnancy. 7, 2019, 9-15.
12) Takeda J. et al. Management of disseminated intravascular coagulation associated with placental abruption and measures to improve outcomes. Obstet Gynecol Sci. 62, 2019, 299-306.
13) Takeda J. et al. Hemostasis for Massive Hemorrhage during Cesarean Section. IntechOpen. DOI : 10.5772/intechopen. 86394
P.169 掲載の参考文献
1) Hasegawa J. et al. Prediction of risk for vasa previa at 9-13 weeks' gestation. J Obstet Gynaecol Res. 37, 2011, 1346-51.
2) Hasegawa J. et al. Analysis of the ultrasonographic findings predictive of vasa previa. Prenat Diagn. 30, 2010, 1121-25.
3) Hasegawa J. et al. Cord insertion into the lower third of the uterus in the first trimester is associated with placental and umbilical cord abnormalities. Ultrasound Obstet Gynecol. 28, 2006, 183-86.
4) Hasegawa J. et al. Detection of umbilical venous constriction by Doppler flow measurement at midgestation. Ultrasound Obstet Gynecol. 36, 2010, 196-201.
5) Strong Jr, TH. et al. The umbilical coiling index. Am J Obstet Gynecol. 170, 1994, 29-32.
6) 大瀬寛子ほか. 臍帯巻絡の分娩経過に与える影響の部位・回数別検討. 日本周産期・新生児医学会雑誌. 49, 2013, 256-260.
7) Hasegawa J. et al. Clinical risk factors for poor neonatal outcomes in umbilical cord prolapse. J Matern Fetal Neonatal Med. 29, 2016, 1652-56.
8) Hasegawa J. et al. The use of balloons for uterine cervical ripening is associated with an increased risk of umbilical cord prolapse : population based questionnaire survey in Japan. BMC Pregnancy Childbirth. 15, 2015, 4.
9) Barrett JM. Funic reduction for the management of umbilical cord prolapse. Am J Obstet Gynecol. 165, 1991, 654-57.
10) Hasegawa J. et al. Do fetal heart rate deceleration patterns during labor differ between various umbilical cord abnormalities? J Perinat Med. 37, 2009, 276-80.
11) Hasegawa J. Ultrasound screening of umbilical cord abnormalities and delivery management. Placenta. 62, 2018, 66-78.
12) Takita H. et al. Antenatal ultrasound screening using check list before delivery for predicting a non-reassuring fetal status during labor. J Matern Fetal Neonatal Med. 31 (1), 2018, 1-6.
P.173 掲載の参考文献
1) American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 181. Prevention of Rh D Alloimmunization. Obstet Gynecol. 130 (2), 2017, e57-70.
3) Martinez-Portilla RJ. et al. Performance of fetal middle cerebral artery peak systolic velocity for prediction of anemia in untransfused and transfused fetuses : systematic review and meta-analysis. Ultrasound Obstet Gynecol. 54 (6), 2019, 722-31.
4) Moise Jr, KJ. "Red cell alloimmunization". Obstetrics Normal and Problem Pregnancies. 7th ed. Amsterdam, Elsevier, 2017, 770-85.
5) 日本周産期・新生児医学会編集. 胎児輸血実施マニュアル. 東京, 日本周産期・新生児医学会, 2017.
6) Klumper FJ. et al. Benefits and risks of red-cell transfusion after 32 weeks gestation. Eur J Obstet Gynecol Reprod Biol. 92 (1), 2000, 91-6.
7) Ruma MS. et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol. 196 (2), 2007, 138.e1-6.
8) Zwiers, C. et al. Postponing early intrauterine transfusion with intravenous immunoglobulin treatment : the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 219 (3), 2018, 291.e1-9.
9) Moise Jr, KJ. "RhD alloimmunization : Prevention of RhD alloimmunization in pregnancy". UpToDate. https://www.uptodate.com/contents/prevention-of-rhd-alloimmunization-in-pregnancy?topicRef=6802&source=see_link#H3932833600
10) Bowman JM. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given?. Am J Obstet Gynecol. 151 (3), 1985, 289-94.
11) Cunningham FG. et al. "Fetal Disorders". Williams Obstetrics. 25th ed. New York, McGraw-Hill Education, 2018, 300-14.
12) Moise Jr KJ. et al. "Hemolytic Disease of the Fetus and Newborn". Creasy and Resnik's Maternal-Fetal Medicine. 8th ed. Amsterdam, Elsevier. 2019. 632-44.
P.183 掲載の参考文献
1) Arora N. et al. Microbial Vertical Transmission during Human Pregnancy. Cell Host Microbe. 21 (5), 2017, 561-7.
2) Racicot K. et al. Risks associated with viral infections during pregnancy. J Clin Invest. 127 (5), 2017, 1591-9.
3) Leon-Juarez M. et al. Cellular and molecular mechanisms of viral infection in the human placenta. Pathog Dis. 75 (7), 2017, ftx093.
4) Crocker IP. et al. Syncytiotrophoblast degradation and the pathophysiology of the malaria-infected placenta. Placenta. 25 (4), 2004, 273-82.
5) Duaso J. et al. Trypanosoma cruzi induces apoptosis in ex vivo infected human chorionic villi. Placenta. 32 (5), 2011, 356-61.
6) Robbins JR. et al. Placental syncytiotrophoblast constitutes a major barrier to vertical transmission of Listeria monocytogenes. PLoS Pathog. 6 (1), 2020, e1000732.
7) Robbins JR. et al. Tissue barriers of the human placenta to infection with Toxoplasma gondii. Infect Immun. 80 (1), 2012, 418-28.
8) Lee JK. et al. Recent Updates on Research Models and Tools to Study Virus-Host Interactions at the Placenta. Viruses. 12 (1), 2019, 5.
9) Blanc WA. "Pathology of the placenta, membranes, and umbilical cord in bacterial, fungal, and viral infections in man". Perinatal Disease. Vol. 22 in International Academy of Pathological Monography. Naeye, RL, et al. eds. Baltimore, Williams & Wilkins, 1981, 67-132.
10) 中山雅弘. "胎盤胎児面の観察とその異常". 目で見る胎盤病理. 東京, 医学書院, 2002, 19-25.
11) Redline RW. et al. Amniotic infection syndrome : Nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. 6 (5), 2003, 435-48.
12) Khong TY. et al. Sampling and Definitions of Placental Lesions : Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med. 140 (7), 2016, 698-713.
13) Lencki SG. et al. Maternal and umbilical cord serum interleukin levels in preterm labor with clinical chorioamnionitis. Am J Obstet Gynecol. 170 (5Pt1), 1994, 1345-51.
14) Romero R. et al. Clinical chorioamnionitis at term I : microbiology of the amniotic cavity using cultivation and molecular techniques. J Perinat Med. 43 (1), 2015, 19-36.
15) Gibbs RS. et al. A randomized trial of intrapartum versus immediate postpartum treatment of women with intra-amniotic infection. Obstet Gynecol. 72 (6), 1988, 823-8.
16) Higgins RD. et al. Chorioamnionitis Workshop Participants : Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis : Summary of a Workshop. Obstet Gynecol. 127 (3), 2016, 426-36.
17) Ueno T. et al. Eukaryote-made thermostable DNA polymerase enables rapid PCR-based detection of mycoplasma, ureaplasma and other bacteria in the amniotic fluid of preterm labor cases. PLoS One. 10 (6), 2015, e0129032.
18) Yoneda S. et al. Antibiotic therapy increases the risk of preterm birth in preterm labor without intra-amniotic microbes, but may prolong the gestation period in preterm labor with microbes, evaluated by rapid and high-sensitive PCR system. Am J Reprod Immunol. 75 (4), 2016, 440-50.
P.186 掲載の参考文献
1) Regan JA. et al. The epidemiology of group B streptococcal colonization in pregnancy. Vaginal Infections and Prematurity Study Group. Obstet Gynecol. 77 (4), 1991, 604-10.
2) Matsubara K. et al. Group B streptococcal disease in infants in the first year of life : a nationwide surveillance study in Japan, 2011-2015. Infection. 45 (4), 2017, 449-58.
2) 国立感染症研究所・感染症疫学センター. 先天性風疹症候群とは. https://www.niid.go.jp/niid/ja/kansennohanashi/429-crs-intro.html [2020. 4. 20]
3) 国立感染症研究所. HI価とEIA価の相関性および抗体価の読み替えに関する検討. 改訂版. 2020. https://www.niid.go.jp/niid/images/idsc/disease/rubella/RubellaHI-EIAtiter_Ver4.pdf [2020. 4. 20]
3) Prevention of Group B Streptococcal Early-Onset Disease in Newborns : ACOG Committee Opinion, Number 797. Obstet Gynecol. 135 (2), 2020, e51-72.
4) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ603 正期産新生児の早発型B群溶血性レンサ球菌 (GBS) 感染症を予防するためには? ". 産婦人科診療ガイドライン : 産科編 2020. 2020, 297-9.
4) 奥田美加ほか. 妊婦における風疹抗体価. 産婦人科治療, 95 (1), 2007, 55-60.
5) 日本環境感染学会. 医療関係者のためのワクチンガイドライン 第3版. 2020. http://www.kankyokansen.org/uploads/uploads/files/jsipc/vaccine-guideline_03(3).pdf
5) Verani JR. et al. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease-revised guidelines from CDC, 2010. MMWR Recomm Rep. 59 (RR-10), 2010, 1-36.
6) 尾崎さゆ里ほか. 多施設合同検討で得られたGBSスクリーニング検査における増菌培養の有用性. 医学検査. 70 (2), 2021, 267-72.
7) 丹野大樹ほか. GBSスクリーニング検査における新規GBS 増菌培地の基礎的検討とラテックス凝集法併用の有用性. 医学検査. 70 (1), 2021, 15-22.
P.190 掲載の参考文献
1) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ605 妊婦における風疹罹患の診断と児への対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 304-7.
P.194 掲載の参考文献
1) 山田秀人 (研究代表者). 先天性サイトメガロウイルス感染症対策のための妊婦教育の効果の検討, 妊婦・新生児スクリーニング体制の構築及び感染新生児の発症リスク同定に関する研究. 厚生労働科学研究費補助金 (成育疾患克服等次世代育成基盤研究事業) 平成23~24年度総合研究報告書.
2) Morton CC, Nance WE. Newborn hearing screening-A silent revolution. N Engl J Med. 354 (20), 2006, 2151-64.
3) Tanimura K. et al. Universal Screening with Use of Immunoglobulin G Avidity for Congenital Cytomegalovirus Infection. Clin Infect Dis. 65 (10), 2017, 1652-8.
4) Puhakka L. et al. Primary versus non-primary maternal cytomegalovirus infection as a cause of symptomatic congenital infection? : register-based study from Finland. Infect Dis (Auckl). 49 (6), 2017, 445-53.
5) Yamada H. et al. A cohort study of the universal neonatal urine screening for congenital cytomegalovirus infection. J Infect Chemother. 26 (8), 2020, 790-4.
6) Kobayashi Y. et al. Low total IgM values and high cytomegalovirus loads in the blood of newborns with symptomatic congenital cytomegalovirus infection. J Perinat Med. 43 (2), 2015, 239-43.
7) Yamada H. et al. Clinical factor associated with congenital cytomegalovirus infection in pregnant women with non-primary infection. J Infect Chemother. 24 (9), 2018, 702-6.
8) Uchida A. et al. Clinical factors associated with congenital cytomegalovirus infection : A cohort study of pregnant women and newborns. Clin Infect Dis. 71 (11), 2020, 2833-39.
9) Liesnard C. et al. Prenatal diagnosis of congenital cytomegalovirus infection : prospective study of 237 pregnancies at risk. Obstet Gynecol. 95 (6), 2000, 881-8.
10) Kimberlin DW. et al. Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. N Engl J Med. 372 (10), 2015, 933-43.
11) Vauloup-Fellous C. et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? : Results of a 3-year prospective study in a French hospital. J Clin Virol. 46 (SUPPL. 4), 2009, S49-53.
P.198 掲載の参考文献
1) Dunn D. et al. Mother-to-child transmission of toxoplasmosis : Risk estimates for clinical counselling Lancet. 353 (9167), 1999, 1829-33.
2) 母子感染の予防と診療に関する研究班. トキソプラズマ妊娠管理マニュアル 2020年1月10日 (第4版). http://cmvtoxo.umin.jp/doc/toxoplasma_manual_20200116.pdf [2021. 12. 26]
P.203 掲載の参考文献
1) 厚生労働省. 平成30年結核登録者情報調査年報集計. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000175095_00002.html [2020. 5. 7]
2) 日本結核病学会. 結核診療ガイド. 東京, 南江堂, 2018, 154p.
3) Mathad JS. et al. Tuberculosis in pregnant and postpartum women : epidemiology, management, and research gaps. Clin Infect Dis. 55, 2012, 1532-49.
4) Jana N. et al. Perinatal outcome in pregnancies complicated by pulmonary tuberclosis. Int J Gynaecol Obstet. 44, 1994, 119-24.
5) Tripathy SN. Tuberclosis and pregnancy. Int J Gynaecol Obstet 80 : 247-253, 2003 Casper GR. et al. Management guidelines for M. tuberculosis in pregnancy. Aust N Z J Obstet Gynaecol. 35, 1995, 401-5.
6) Jennifer LF. et al. Performance of an Interferon-Gamma Release Assay to Diagnose Latent Tuberculosis Infection During Pregnancy. Obstet Gynecol. 119, 2012, 1088-95.
7) World Health Organization. WHO Guidelines for treatment of tuberculosis 4th edition. Geneva. 2010.
8) Lewinsohn DM. et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines : Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 64, 2017, 111-5.
9) 松田美奈子ほか. 当院における結核合併妊娠の6例. 産婦人科の実際. 68, 2019, 125-9.
10) 水主川純ほか. 当院における結核合併妊娠症例に関する検討. 臨床婦人科産科. 64, 2010, 901-5.
11) 結核予防会結核研究所. 小児結核診療のてびき (改訂版). 2021, 167p.
P.207 掲載の参考文献
1) 厚生労働省. 感染症法に基づく医師及び獣医師の届出について : 梅毒. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-11.html [2020. 5. 4]
2) 国立感染症研究所感染症疫学センター・細菌第一部. 日本の梅毒症例の動向について (2020年4月1日現在). https://www.niid.go.jp/niid/ja/syphilis-m-3/syphilis-idwrs/7816-syphilis-data-20180105.html [2020. 5. 4]
3) Takamatsu K. et al. Annual report of the women's health care committee, Japan Society of Obstetrics and Gynecology, 2017. J Obstet Gynaecol Res. 44, 2018, 13-26.
4) 国立感染症研究所感染症疫学センター. 発生動向調査年別報告数一覧 (全数把握). 2019. https://www.niid.go.jp/niid/ja/ydata/10068-report-ja2019-30.html [2022. 3. 18]
5) 川名敬. 産婦人科感染症の最前線 : 拡がり続ける感染にどう対策するか : HPV, 梅毒. 日本産科婦人科学会雑誌. 71, 2019, 652-9.
P.212 掲載の参考文献
1) 国立感染症研究所麻疹対策技術支援チーム. 改訂 : 最近の知見に基づく麻疹の検査診断の考え方. 2016. http://www.nih.go.jp/niid/images/idsc/disease/measles/pdf01/arugorizumu2016.pdf [2020. 3. 23]
2) Eberhart-Phillips JE. et al. Measles in pregnancy : a descriptive study of 58cases. Obstet Gynecology. 82, 1993, 797-801.
3) 奥田美加ほか. 周産期管理から見た麻疹・風疹感染対策. 日本周産期・新生児医学会雑誌. 44, 2008, 910-2.
4) 笠井正志ほか. 麻疹 : 妊娠中の麻疹罹患への対応と新生児期の麻疹感染. 周産期医学. 32, 2002, 853-6.
5) Sonja A. et al. What Obstetric Health Care Providers Need to Know About Measles and Pregnancy. Obstet Gynecology. 126, 2015, 163-70.
6) 本田義信. 水痘, 麻疹の胎内感染. 周産期医学. 44 (増刊), 2014, 431-5.
7) 国立感染症研究所感染症疫学センター. 医療機関での麻疹対応ガイドライン第七版. https://www.niid.go.jp/niid/images/idsc/disease/measles/guideline/medical_201805.pdf [2020. 3. 23]
P.215 掲載の参考文献
1) 国立感染症研究所. 水痘とは. 2020. (online) https://www.niid.go.jp/niid/ja/kansennohanashi/418-varicella-intro.html [2020. 2. 7]
2) Marin M. et al. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 56 (RR-4), 2007, 1-40.
3) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ611 妊産褥婦の水痘感染については? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 323-5.
4) Lamont RF. et al. Varicella-zoster virus (chickenpox) infection in pregnancy. BJOG. 118 (10), 2011, 1155-62.
5) Enders G. et al. Consequences of varicella and herpes zoster in pregnancy : prospective study of 1739 cases. Lancet. 343 (8912), 1994, 1548-51.
6) Koren G. Congenital varicella syndrome in the third trimester. Lancet. 366 (9497), 2005, 1591-2.
7) Sauerbrei A. et al. Neonatal varicella. J Perinatol. 21 (8), 2001, 545-9.
8) Updated recommendations for use of VariZIG--United States, 2013. MMWR Morbidity and mortality weekly report. 62 (28), 2013, 574-6.
9) Smego RA, Jr. et al. Use of acyclovir for varicella pneumonia during pregnancy. Obstet Gynecol. 78 (6), 1991, 1112-6.
10) Shields KE. et al. Varicella vaccine exposure during pregnancy : data from the first 5 years of the pregnancy registry. Obstet Gynecol. 98 (1), 2001, 14-9.
P.223 掲載の参考文献
1) 白木和夫. Infectious Agents Surveillance Report. 21, 2000. 74-5.
2) 白木和夫. B型肝炎ワクチンと母子肝炎防止. モダンメディア. 50 (12), 2004, 279-85.
3) 日本小児科学会, 日本小児栄養消化器肝臓学会, 日本産科婦人科学会. B 型感染ウイルス母子感染予防のための新しい指針. 2013. http://www.jpeds.or.jp/uploads/files/HBV20131218.pdf
4) 「C 型肝炎ウイルス等の母子感染防止に関する研究」班. C型感染ウイルス (HCV) キャリア妊婦とその出生児の管理指導指針. 2005. https://www.mhlw.go.jp/shingi/2005/04/dl/s0412-8f1.pdf
5) 田尻仁 (ガイドライン作成委員長). C型肝炎母子感染小児の診療ガイドライン. 日本小児栄養消化器肝臓学会雑誌. 34 (2), 2020, 95-121.
6) 板橋家頭夫 (研究代表者). HTLV-1 母子感染予防対策マニュアル. 厚労行政推進調査事業補助金・成育疾患克服等次世代成育基盤研究事業. https://www.mhlw.go.jp/bunya/kodomo/boshi-hoken16/dl/06.pdf
7) 日本産婦人科医会・日本小児科医会編. HTLV-1 母子感染を防ぐために. 2017. http://www.jaog.or.jp/wp/wp-content/uploads/2017/05/HTLV-1.pdf
8) 日本産婦人科感染症学会. HIV 感染妊娠に関する診療ガイドライン 第2版. 2021. http://hivboshi.org/manual/guideline/2021_guideline.pdf
9) 喜多恒和 (研究代表者). HIV 母子感染予防対策マニュアル 第8版. 2019. http://hivboshi.org/manual/manual/manual8.pdf
10) 安井良則 (主任研究者). 新型インフルエンザ対策 (A/H1N1) 妊娠中の人や授乳中の人へ. 2009. https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/pdf/ninpu_1217_2.pdf
P.231 掲載の参考文献
1) 日本産科婦人科学会編, 産科婦人科用語集・用語解説集. 改訂第4版. 2018.
2) 鈴木昌. シリーズ : 内科医に必要な救急医療 ショック. 日本内科学会雑誌. 100, 1084-8, 2011.
3) 日本産科婦人科学会/日本産婦人科医会 編集・監修, "CQ418-1 産後の異常出血の予防ならびに対応は? ". "CQ418-2 「産科危機的出血」への対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 2020, 260-7.
4) 日本産科婦人科学会/日本産婦人科医会編集・監修, "CQ401 緊急時に備え, 分娩室または分娩室近くに準備しておく医薬品・物品は? ". 産婦人科診療ガイドライン : 産科編 2020. 2020, 193-5.
5) 日本産科婦人科学会, 日本産婦人科医会, 日本周産期・新生児医学会, 日本麻酔科学会, 日本輸血・細胞治療学会. 産科危機的出血への対応指針 (2017年11月改定).
6) 日本外傷学会外傷初期診療ガイドライン改訂第5版編集委員会. "第3章 外傷と循環". 外傷初期診療ガイドライン 改訂第5版. 東京, へるす出版, 2016, 43-59.
7) 厚生労働省医薬・生活衛生局. 血液製剤の使用指針. 2017. https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000161115.pdf覧]
8) 日本麻酔科学会, 日本輸血・細胞治療学会. 危機的出血への対応ガイドライン. 2007.
9) 日本IVR学会. 産科危機的出血に対するIVR施行医のためのガイドライン 2017.
P.235 掲載の参考文献
1) Barton JR. et al. Severe sepsis and septic shock in pregnancy. Obstet Gynecol. 120, 2012, 689-706.
2) Hensley MK. et al. Incidence of Maternal Sepsis and Sepsis-Related Maternal Deaths in the United States. JAMA. 322, 2019, 890-92.
3) Bauer ME. et al. Risk Factors, Etiologies, and Screening Tools for Sepsis in Pregnant Women : A Multicenter Case-Control Study. Anesth Analg. 129, 2019, 1613-20.
4) Vincent JL. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22, 1996, 707-10.
5) Seymour CW. et al. Assessment of Clinical Criteria for Sepsis : For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 315, 2016, 762-74.
6) 一般社団法人日本集中治療医学会・一般社団法人日本救急医学会日本版敗血症診療ガイドライン2020特別委員会編集. 日本版敗血症診療ガイドライン 2020. 日本集中治療医学会雑誌. 28, Suppl, 2021.
7) Royal College of Obstetricians & Gynaecologists. Bacterial sepsis in pregnancy. Green-top Guideline 2012. No. 64a.
8) Acosta CD. et al. Severe maternal sepsis in the UK, 2011-2012 : a national case-control study. PLoS Med. 11, 2014, e1001672.
9) Tanaka H. et al. The most common causative bacteria in maternal sepsis-related deaths in Japan were group A Streptococcus : A nationwide survey. J Infect Chemother. 25, 2019, 41-44.
10) Yamada T. et al. Invasive group A streptococcal infection in pregnancy. J Infect. 60, 2010, 417-24.
11) 宇田川秀雄ほか. 劇症型A群連鎖球菌感染症「分娩型」の臨床像. 日本産科婦人科学会雑誌. 51, 1999, 1141-49. 訂正 52, 2000, 657.
12) 小林康祐. 劇症型A群レンサ球菌感染症「分娩型」における血液凝固線溶系. Thrombosis Medicine. 9, 2019, 42-46.
P.240 掲載の参考文献
1) Katz V. et al. Perimortem cesarean delivery. Obstet Gynecol. 68, 1986, 571-6.
2) Katz V. et al. Perimortem cesarean delivery : were our assumptions correct? Am J Obstet Gynecol. 192, 2005, 1916-20.
3) Einav S. et al. Maternal cardiac arrestand perimortem caesarean delivery : evidence or expert-based? Resuscitation. 83, 2012, 1191-200.
4) Perinatal Critical Care Course 運営協議会. 周産期初期診療アルゴリズム : PC3 ピーシーキューブ公式コースガイド. 荻田和秀ほか編. 大阪, メディカ出版, 2017, 128p.
5) Benson MD. et al. Maternal collapse : Challenging the four-minute rule. EBioMedicine. 6, 2016, 253-7.
6) Beckett VA. et al. The CAPS study : incidence, management and outcomes of cardiac arrest in pregnancy in the UK : a prospective, descriptive study. BJOG 124 (9), 2017, 1374-81.
7) Goto M. et al. Perimortem cesarean delivery and subsequent emergency hysterectomy : new strategy for maternal cardiac arrest. Acute Med Surg. 4 (4), 2017, 467-71.
8) Battaloglu E. et al. Management of pregnancy and obstetric complications in prehospital trauma care : faculty of prehospital care consensus guidelines. Emerg Med J. 34 (5), 2017, 318-25.
P.244 掲載の参考文献
1) 清水可方ほか. A群溶血性連鎖球菌によるToxic schock syndromeの1例. 感染症学雑誌. 67, 1993, 236-9.
2) 宇田川秀雄ほか. A群溶連菌の激烈な敗血症により双胎胎児と母体が突然死した症例. 感染症学雑誌. 67, 1993, 1219-22.
3) Ato M. et al. Incompetence of neutrophils to invasive group A streptococcus is attributed to induction of plural virulence factors by dysfunction of a regulator. PLoS ONE. 3, 2008, e3455.
4) 宇田川秀雄. A群レンサ球菌. 産婦人科の実際. 55, 2006, 363-70.
5) 所伸介ほか. 当院で経験した劇症型A群レンサ球菌感染症「分娩型」の一例. 滋賀県産科婦人科雑誌. 7, 2015, 55-60.
6) 宇田川秀雄ほか. 劇症型A群レンサ球菌感染症「分娩型」の臨床像. 日本産科婦人科学会雑誌. 51, 1999, 1141-9. (訂正記事 52, 2000, 657.)
7) Centor RM. et al. The diagnosis of strep throat in adults in the emergency room. Med Decis Making. 1, 1981, 239-46.
8) The working group on severe streptococcal infection. Definiting the group A streptococcal toxic shock like syndrome. JAMA. 269, 1993, 390-1.
9) 日本版敗血症診療ガイドライン2020特別委員会編. CQ1 : 敗血症の定義と診断. 日本版敗血症診療ガイドライン 2020. 日本集中治療医学会雑誌. 28 (Suppl), 2021, S21-6.
P.248 掲載の参考文献
1) Porak C. De L'influence reciproque de la grossesse et del maladies du Coeur [thesis]. Medical Faculty of Paris, France, 1880.
2) Ritchie C. Clinical contribution to the pathology, diagnosis, and treatment of certain chronic diseases of the heart. Edinburgh Med Surg J. 185, 1849, 333-42.
3) Hull E. et al. Toxic postpartal heart disease. N Orleans Med Surg J. 89, 1937, 550.
4) Hull E. et al. Postpartal heart failure. Southern Med J. 31, 1938, 265.
5) Demakis JG. et al. Peripartum cardiomyopathy. Circulation. 44, 1971, 964-8.
6) Demakis JG. et al. Natural course of peripartum cardiomyopathy. Circulation. 44, 1971, 1053-61.
7) Gunderson EP. et al. Epidemiology of peripartum cardiomyopathy : Incidence, predictors, and outcomes. Obstet Gynecol. 118, 2011, 583-91.
8) Witlin AG. et al. Peripartum cardiomyopathy : Anominous diagnosis. Am J Obstet Gynecol. 176, 1997, 182-8.
9) Brar SS. et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 100, 2007, 302-4.
10) Tanaka H. et al. The increase in the rate of maternal deaths related to cardiovascular disease in Japan from 1991-1992 to 2010-2012. J Cardiol. 69, 2017, 74-8.
11) Bello N. et al. The relationship between pre-eclampsia and peripartum cardiomyopathy : a systematic review and meta-analysis. J Am Coll Cardiol. 62, 2013, 1715-23.
12) Kao DP. et al. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart Fail. 1, 2013, 409-16.
13) Fong A. et al. Clinical morbidities, trends, and demographics of eclampsia : a population-based study. Am J Obstet Gynecol. 209, 2013, 229.e1-7.
14) Kolte D. et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States : a nationwide population-based study. J Am Heart Assoc. 3, 2014, e001056.
15) Halkein J. et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 123, 2013, 2143-54.
16) Pearson GD. et al. Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 283, 2010, 1183-8.
17) Kamiya CA. et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders : Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 75, 2011, 1975-81.
18) Elkayam U. et al. Maternal and fetal outcomes od subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 344, 2001, 1567-71.
P.255 掲載の参考文献
1) Kanayama N. et al. Amniotic fluid embolism : pathophysiology and new strategies for management. J Obstet Gynaecol Res. 40, 2014, 1507-17.
2) Clark SL. Amniotic Fluid Embolism. Obstet Gynecol. 123, 2014, 337-48.
3) Clark SL. et al. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol. 215, 2016, 408-12.
4) Oda T. et al. Japanese viewpoint on amniotic fluid embolism. Am J Obstet Gynecol. 217, 2017, 91.
5) Farhana M. et al. Histological characteristics of the myometrium in the postpartum hemorrhage of unknown etiology : a possible involvement of local immune reactions. J Reprod Immunol. 110, 2015, 74-80.
6) Jain D. et al. Acute inflammation in the uterine isthmus coincides with postpartum acute myometritis in the uterine body involving refractory postpartum hemorrhage of unknown etiology after cesarean delivery. J Reprod Immunol. (in press)
7) Shen Y. et al. Elevated bradykinin receptor type 1 expression in postpartum acute myometritis : Possible involvement in augmented interstitial edema of the atonic gravid uterus. J Obstet Gynaecol Res. 45, 2019, 1553-61.
8) 小田智昭ほか. 死戦期における血液凝固線溶系の病態生理 : 羊水塞栓症における血液凝固線溶系と補体系. Thrombosis Medicine. 9, 2019, 36-41.
9) Oda T. et al. Amniotic fluid as a potent activator of blood coagulation and platelet aggregation : Study with rotational thromboelastometry. Thromb Res. 172, 2018, 142-9.
10) Oda T. et al. Consumptive Coagulopathy Involving Amniotic Fluid Embolism : The Importance of Earlier Assessments for Interventions in Critical Care. Crit Care Med. 48, 2020, e1251-9.
11) 妊産婦死亡症例検討評価委員会/日本産婦人科医会. 母体安全への提言 2020. 2021, 76-7.
12) 日本産科婦人科学会周産期委員会. 羊水塞栓症の子宮所見の臨床的検討. 日本産科婦人科学会雑誌. 69, 2017, 1467-9.
13) 溝端康光. Damage control surgery : 理論的背景と実際. 救急・集中治療. 26, 2014, 995-1003.
14) Todo Y. et al. Therapeutic application of C1 esterase inhibitor concentrate for clinical amniotic fluid embolism : a case report. Clin Case Rep. 3, 2015, 673-5.
15) Clark SL. Successful pregnancy outcomes after amniotic fluid embolism. Am J Obstet Gynecol. 167, 1992, 511-2.
16) Moaddab A. et al. Reproductive decisions after the diagnosis of amniotic fluid embolism. Eur J Obstet Gynecol Reprod Biol. 211, 2017, 33-6.
P.263 掲載の参考文献
1) Meissner MH. et al. "The epidemiology and natural history of acute deep vein thrombosis". Handbook of venous disorders. Gloviczki P. et al. eds. London, Arnold, 2001, 38-48.
2) Sugimura M. et al. Detection of decreased response to activated protein C in venous thrombosis associated with pregnancy by endogenous thrombin potential-based assay. Semin Thromb Hemost. 25, 1999, 497-502.
3) Hirai K. et al. A rapid activated protein C sensitivity test as a diagnostic marker for a suspected venous thromboembolism in pregnancy and puerperium. Gynecol Obstet Invest. 72, 2011, 55-62.
4) Sugimura M. et al. Detection of marked reduction of sensitivity to activated protein C prior to the onset of thrombosis during puerperium as detected by endogenous thrombin potential-based assay. Thromb Haemost. 82, 1999, 1364-5.
5) 小林隆夫ほか. 産婦人科血栓症調査結果の最終報告と静脈血栓症予防ガイドラインについて. 日本産婦人科・新生児血液学会誌. 14, 2004, 5-6.
6) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン改定班. "深部静脈血栓症". 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018, 52-68.
7) 日本産科婦人科学会/日本産婦人科医会 編集・監修. 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020. 18-21. "CQ004-3 妊娠・産褥期に深部静脈血血栓症や肺血栓塞栓症の発症を疑ったら? ".
8) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン改定班. "急性肺血栓塞栓症". 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018, 6-40.
9) 佐久間聖仁. 急性肺血栓塞栓症の診断 : 今後の方向性. Ther Res. 30, 2009, 744-7.
10) Lockwood C. Thrombosis, thrombophilia, and thromboembolism : clinical updates in women's health care. American College of Obstetrics and Gynecologists. Vol.6, 2012.
11) 日本産科婦人科学会/日本産婦人科医会 編集・監修. 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020. 8-12. "CQ004-1 妊娠中の静脈血栓塞栓症 (VTE) の予防は? ".
12) 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン改定班. "肺血栓塞栓症/深部静脈血栓症の予防". 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018, 68-77.
13) Warkentin TE. et al. Heparin-induced thrombocytopenia in patients treated with low- molecular-weight heparin or unfractionated heparin. N Eng J Med. 332, 1995, 1330-5.
14) 日本産科婦人科学会/日本産婦人科医会 編集・監修. 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020. 13-7. "CQ004-2 分娩後の静脈血栓塞栓症 (VTE) の予防は? ".
15) Bates SM. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. American College of Chest Physicians Evidence-Based Clnical Practice Guidelines (9th Edition). Chest. 141, 2012, 691736.
P.269 掲載の参考文献
1) 日本産婦人科医会妊産婦死亡症例検討評価委員会. 母体安全への提言 2018. Vol.9. 東京, 日本産婦人科医会, 2019.
2) 日本母体救命システム普及協議会 (J-CIMELS) 総監修. J-MELS「日本母体救命システム」アドバンスコース プログラム開発・改定委員会監修. 母体救命アドバンスガイドブックJ-MELS編集委員会編集. 母体救命アドバンスガイドブックJ-MELS. 東京, へるす出版, 2017, 328p.
3) 日本産科婦人科学会/日本産婦人科医会監修・編集. "CQ309-3 妊産褥婦がけいれんを起こしたときの対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 177-80.
4) 循環器病の診断と治療に関するガイドライン合同研究班. 失神の診断・治療ガイドライン. 2012年改訂版. 東京, 日本循環器学会, 2012.
5) 日本臨床検査医学会ガイドライン作成委員会. 臨床検査のガイドラインJSLM2018. 東京, 日本臨床検査医学会, 2019.
6) 日本神経学会監修, 「てんかん治療ガイドライン」作成委員会. てんかん治療ガイドライン 2018. 東京, 日本神経学会, 2018.
7) 日本母体救命システム普及協議会・京都産婦人科救急診療研究会編著. 産婦人科必修 母体急変時の初期対応. 第3版. 2020, 大阪, メディカ出版, 368p.
8) 太田冨雄ほか. 急性期意識障害の新しいGradingとその表現方法 (いわゆる3-3-9度方式). 第3回脳卒中の外科研究会講演集. 1975, 161-9.
9) Jennett, B. et al. Aspects of coma after severe head injury. Lancet. 1, 1977, 878-81.
P.276 掲載の参考文献
1) 妊産婦死亡症例検討評価委員会/日本産婦人科医会. 母体安全への提言 2019 (Vol.10). 2020, 83p.
2) 日本母体救命システム普及協議会ほか. 産婦人科必修 母体急変時の初期対応 第3版 : JCIMELS 公認講習会ベーシックコーステキスト. 大阪, メディカ出版, 2020, 368p.
3) Perinatal Critical Care Course運営協議会. 周産期初期診療アルゴリズム : PC3公式コースガイド. 荻田和秀ほか編. 大阪, メディカ出版, 2017, 128p.
4) The PROMPT Editional Teams. PROMPT (Practical Obstetric Multi-Professional Training) 3rd Edition. Cambridge, Cambridge University Press. 2018, 328p.
5) Paterson-Brown S. Managing Obstetric Emergencies and Trauma : The MOET Course Manual 3rd Edition. Cambridge University Press. 2016, 510p.
P.279 掲載の参考文献
1) 厚生労働省. 周産期医療体制整備指針. 2010.
2) American College of Obstetrics and Gynecologists Committee on Professional Standards. Standards for obstetricsgynecologic services. 7th ed. Washington, DC, 1989.
3) National Institute for Health and Care Excellence. Cesarean section guidline. London (UK) : National Institute for Health and Care Excellence ; 2011.
4) Tolcher MC. et al. Decision-to-incision time and neonatal outcomes. Obstet Gynecol. 123, 2014, 536-48.
5) Royal College of Obstetricians and Gynecologists. Umbilical cord prolapse. Green-top Guideline no.50. London (GB), RCOG, 2014.
6) Steer PJ. Written consent should not be obtained at the time of emergency caesarean section. BJOG. 125, 2018, 1757.
7) Chervenak FA, McCullough LB. Written consent should not be obtained at the time of emergency caesarean section : AGAINST : Written consent should be obtained. BJOG. 125, 2018, 1756.
8) 吉村聖子ほか. 麻酔科当直体制でない当院での超緊急帝王切開への取り組み. 日本臨床麻酔学会誌. 38, 2018, S232.
9) Baskett TF. Preparedness for emergency "Crash"caesarean section. J Obstet Gynecol Can. 37, 2015, 1116-7.
10) Burke II JJ. "Chapter 7 Incisions for Gynecologic Surgery". Te Linde's Operative Gynecology. 12th ed. Handa VL, Le LV. eds. Philadelphia, Wolters Kluwer, 2020, 128-55.
11) 鈴木眞嗣ほか. 超緊急帝王切開シミュレーションの振り返りにおける4画面動画再生の有用性の検討. 分娩と麻酔. 100, 2018, 8-11.
P.285 掲載の参考文献
1) 母子衛生研究会編. 母子保健の主なる統計. 平成30年度. 東京, 母子保健事業団. 2019, 49.
2) Hogberg U. et al. Infant mortality of very preterm infants by mode of delivery, institutional policies and maternal diagnosis. Acta Obstet Gynecol Scand. 86, 2007, 693-700.
3) Redman ME. et al. Cesarian delivery rates at the threshold of viability. Am J Obstet Gynecol. 187, 2002, 73-6.
4) Toijonen AE. et al. A comparison of risk factors for breech presentation in preterm and term labor : a nationwide, population-based 2020, 393-403.
5) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ403 帝王切開既往妊婦が経腟分娩 (TOLAC, trial of labor after cesarean delivery) を希望した場合は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 199-201.
6) Al-Zirqi I. et al. Risk factors for complete uterine rupture. Am J Obstet Gynecol. 216, 2017, 165.e1-8.
7) David M. et al. Nitroglycerin to facilitate fetal extraction during cesarea delivery. Obstet Gynecol. 91, 1998, 119-124.
8) David M. et al. Nitroglycerin application during cesarean delivery ; Plasma levels, fetal/maternal ratio of nitroglycerin, and effects in newborns. Am J Obstet Gynecol. 182, 2000, 955-61.
9) 松田千栄ほか. 帝王切開中に子宮弛緩目的で使用したニトログリセリン200μgの効果. 麻酔. 62, 2013, 390-4.
P.291 掲載の参考文献
1) 日本産科婦人科学会編. 産科婦人科用語集・用語解説集 改訂第4版. 東京, 金原出版, 2018, 326.
2) 妊産婦死亡症例検討評価委員会/日本産婦人科医会. "妊産婦死亡報告事業での事例収集と症例検討の状況について : 2010~2019年に報告され, 事例検討を終了した428例の解析結果 : 妊産婦死亡原因". 母体安全への提言 2019 Vol.10. 2020, 11-15.
3) Anderson JM. et al. Prevention and management of postpartum hemorrhage. Am Fam Physician. 75, 2007, 875-82.
4) 日本母体救命システム普及協議会監修. 母体救命アドバンスガイドブック. 東京, へるす出版, 2017, 17.
5) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "311-1 産後の過多出血の予防ならびに対応は? ". 産婦人科診療ガイドライン : 産科編 2017. 2017, 241-9.
6) WHO. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012. http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf [2021. 10. 22.]
7) Cunningham FG. et al. "Normal Labor and Delivery". Williams Obstetrics. 23 rd ed. Stanford, Appleton & Lange, 2010, 374-409.
8) Leduc D. et al. Active manangemnet of the third stage of labor : preventation and treatment of postpartum hemorrhage. J. Obstet. Gynecol. Can. 31, 2009, 980-93. PMID : 19941729 (Guideline).
9) Bakri YN. Balloon device for control of obstetrical bleeding. Eur J Obstet Gynecol Reprod. 86, 1999, S84.
10) Vedanthham S. et al. Uterine artery embolization : an underused method of controlling pelvic hemorrhage. Am J Obstet Gynecol. 176, 1997, 938.
11) B-Lynch C. et al. The B-Lynch surgical technique for the control of massive postpartum haemorrhage : analternative to hysterectomy? Five cases reported. Br J Obstet Gynecol. 104, 1997, 372-5.
12) 橋口幹夫. "分娩時異常出血". 改訂3版 MFICUマニュアル. 全国周産期医療 (MFICU) 連絡協議会編著. 大阪, メディカ出版, 2015, 456-63.
13) Cho JH. et al. Hemostatic suturing technique for uterine bleeding during cesarean delivery. Obstet Gynecol. 96, 2000, 129-31.
14) 大村美穂ほか. 母体搬送を受け入れた症例のうち, 産道損傷による分娩後異常出血症例の解析. 日本周産期・新生児医学会誌. 56, 2020, 31-6.
15) 山本晃士. 産科大量出血の病態と輸血治療. Japanese Journal of Transfusion and Cell Therapy. 58, 2012, 745-52.
16) Oberg AS. et al. Patterns of recurrence of postpartum hemorrhage in a large population-based cohort. Am J Obstet Gynecol. 210, 2014, 229.e1-e8.
P.296 掲載の参考文献
1) 日本産科婦人科学会編. 産科婦人科用語集・用語解説集 改訂4版. 東京, 日本産科婦人科学会, 2018, 130.
2) Cunningham FG, et al. "Chapter 41 Obstetric hemorrhage". Williams Obstetrics. 24th ed. New York, McGraw-Hill Professional, 2014, 780-8.
3) Baskett TF. Acute uterine inversion : a review of 40 cases. J Obstet Gynaecol Can. 24 (12), 2002, 953-6.
4) Coad SL, et al. Risk and consequences of puerperal uterine inversion in the United States, 2004 through 2013. Am J Obstet Gynecol. 217, 2017, 377.e1.
5) Ogah K, Munjuluri N. Complete uterine inversion after vaginal delivery. J Obstet Gynaecol. 31 (3), 2011, 265-6.
6) Witteveen T, et al. Puerperal uterine inversion in the Netherlands : a nationwide cohort study. Acta Obstet Gynecol Scand. 92 (3), 2013, 334-7.
7) Dali SM, et al. Puerperal inversion of the uterus in Nepal : case reports and review of literature. J Obstet Gynaecol Res. 23 (3), 1997, 319-25.
8) Deneux-Tharaux C, et al. Effect of routine controlled cord traction as part of the active management of the third stage of labour on postpartum haemorrhage : multicentre randomised controlled trial (TRACOR). BMJ. 346, 2013, f1541.
9) Pena-Marti G, Comunian-Carrasco G. Fundal pressure versus controlled cord traction as part of the active management of the third stage of labour. Cochrane Database Syst Rev. (4), 2007, CD005462.
10) Beringer RM, Patteril M. Puerperal uterine inversion and shock. Br J Anaesth. 92 (3), 2004, 439-41.
11) Pauleta JR, et al. Ultrasonographic diagnosis of incomplete uterine inversion. Ultrasound Obstet Gynecol. 36 (2), 2010, 260-1.
12) Harris BA, Jr. Acute puerperal inversion of the uterus. Clin Obstet Gynecol. 27 (1), 1984, 134-8.
13) Anderson JM, Etches D. Prevention and management of postpartum hemorrhage. American family physician. 75 (6), 2007, 875-82.
14) Robson S, et al. A new surgical technique for dealing with uterine inversion. Aust N Z J Obstet Gynaecol. 45 (3), 2005, 250-1.
15) Sangwan N, et al. Puerperal uterine inversion associated with unicornuate uterus. Arch Gynecol Obstet. 280 (4), 2009, 625-6.
16) 平松祐司. 子宮内反症整復術. 産婦人科治療. 94 (2), 2007, 215-21.
17) Vinatier D, et al. Utilization of intravenous nitroglycerin for obstetrical emergencies. Int J Gynaecol Obstet. 55 (2), 1996, 129-34.
18) Axemo P, et al. Intravenous nitroglycerin for rapid uterine relaxation. Acta Obstet Gynecol Scand.77 (1), 1998, 50-3.
19) Matsubara S, et al. Uterine compression suture against impending recurrence of uterine inversion immediately after laparotomy repositioning. J Obstet Gynaecol Res. 35 (4), 2009, 819-23.
P.302 掲載の参考文献
1) 日本産婦人科学会・日本産婦人科医会編集・監修. "CQ403 帝王切開既往妊婦が経腟分娩 (TOLAC, trial of labor after cesarean delivery) を希望した場合は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 199-201.
2) Guise JM. et al. Vaginal birth after cesarean : new insights. Evid Rep Technol Assess (Full Rep) 2010, 1-397.
3) Landon MB. et al. Vaginal Birth after Cesarean Delivery. 7th ed. Obstetrics : Normal and Problem Pregnancies, Gabbe SG. ed. Philadelphia, Elsevier, 2017.
4) Landon MB. et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med. 351, 2004, 2581-9.
5) Silver RM. et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 107, 2006, 1226-32.
6) Huang WH. et al. Interdelivery interval and the success of vaginal birth after cesarean delivery. Obstet Gynecol. 99, 2002, 41-4.
7) Lannon SM. et al. Uterine rupture risk after periviable cesarean delivery. Obstet Gynecol. 125, 2015, 1095-100.
8) Bujold E. et al. Prediction of complete uterine rupture by sonographic evaluation of the lower uterine segment. Am J Obstet Gynecol. 201, 2009, 320 e1-6.
9) Cunningham FG. et al. Prior Cesarean Delivery, in Williams Obstetrics. New York, McGraw-Hill Education, 2018, 591-603.
10) Holmgren C. et al. Uterine rupture with attempted vaginal birth after cesarean delivery : decision-to-delivery time and neonatal outcome. Obstet Gynecol. 119, 2012, 725-31.
11) Kaczmarczyk M. et al. Risk factors for uterine rupture and neonatal consequences of uterine rupture : a population-based study of successive pregnancies in Sweden. BJOG. 114, 2007, 1208-14.
12) Spong CY. et al. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. Obstet Gynecol. 110, 2007, 801-7.
13) Landon MB. et al. The MFMU Cesarean Registry : factors affecting the success of trial of labor after previous cesarean delivery. Am J Obstet Gynecol. 193, 2005, 1016-23.
14) Nakamura K. et al. Labor after cesarean delivery managed without induction or augmentation of labor. Birth. 44, 2017, 363-8.
P.306 掲載の参考文献
1) Hannah ME, et al. Planned caesarean section versus planned vaginal birth for breech presentation at term : a randomized multicenter trial. Term Breech Trial Collaborative Group. Lancet.356, 2000, 1375-83.
2) ACOG committee opinion No.745. Mode of Term Singleton Delivery. Obstet Gynecol. 132, 2018, e60-3.
3) 竹田省ほか編. CG動画でわかる! 肩甲難産・骨盤位への対応. 東京, メジカルビュー社, 2019, 124p.
4) 日本産婦人科学会・日本産婦人科医会編集・監修. "CQ402 単胎骨盤位の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 196-8.
5) Hofmeyr GJ. Delivery of the singleton fetus in breech presentation. UpToDate R. May 2021. https://www.uptodate.com/contents/delivery-of-the-singleton-fetus-in-breech-presentation [2021. 7. 29.]
P.310 掲載の参考文献
1) Leung TY. et al. Effect of twin-to-twin delivery interval on umbilical cord blood gas in the second twins. BJOG. 109 (1), 2002, 63-7.
2) Cunningham FG. et al. eds. Williams Obstetrics 25th ed. New York, McGraw Hill 2018, 887-91.
3) Chauhan SP. et al. Delivery of the nonvertex second twin : breech extraction versus external cephalic version. Am J Obstet Gynecol. 173 (4), 1995, 1015-20.
4) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ418-2 「産科危機的出血」への対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 2020, 264-7.
5) Page JM. et al. The risk of stillbirth and infant death by each additional week of expectant management stratified by maternal age. Am J Obstet Gynecol. 209 (4), 2013, 375.e1-7.
6) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ415-1 子宮収縮薬 (オキシトシン, プロスタグランジンF2αならびにプロスタグランジンE2錠の三者) 投与開始前に確認すべきことは? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 245-9.
7) Dodd JM. et al. Elective birth at 37 weeks' gestation for women with an uncomplicated twin pregnancy. Cochrane Database Syst Rev. 2014, Feb 10 ; (2) : CD003582.
8) Committee on Practice Bulletins-Obstetrics ; Society for Maternal-Fetal Medicine. Practice Bulletin No. 169 : Multifetal Gestations : Twin, Triplet, and Higher-Order Multifetal Pregnancies. Obstet Gynecol. 128 (4), 2016, e131-46.
9) MONOMONO Working Group. Inpatient vs outpatient management and timing of delivery of uncomplicated monochorionic monoamniotic twin pregnancy : the MONOMONO study. Ultrasound Obstet Gynecol. 53 (2), 2019, 175-83.
10) Oyelese Y. et al. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol. 107 (4), 2006, 927-41.
11) Pestana I. et al. Effect of mode of delivery on neonatal outcome of monochorionic diamniotic twin pregnancies : a retrospective cohort study. J Reprod Med. 58 (1-2), 2013, 15-8.
12) Garabedian C. et al. Intrapartum management of twin pregnancies : are uncomplicated monochorionic pregnancies more at risk of complications than dichorionic pregnancies? Acta Obstet Gynecol Scand. 94 (3), 2015, 301-7.
13) Barrett JF. et al ; Twin Birth Study Collaborative Group. A randomized trial of planned cesarean or vaginal delivery for twin pregnancy. N Engl J Med. 369 (14), 2013, 1295-305. Erratum in : N Engl J Med. 369 (24), 2013, 2364.
14) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ402 単胎骨盤位の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 196-8.
15) Rossi AC. et al. Neonatal outcomes of twins according to birth order, presentation and mode of delivery : a systematic review and meta-analysis. BJOG. 118 (5), 2011, 523-32.
16) Hofmeyr GJ. et al. External cephalic version for breech presentation at term. Cochrane Database Syst Rev. 2015 (4), 2015, CD000083.
17) Hutton EK. et al. External cephalic version for breech presentation before term. Cochrane Database Syst Rev. (7), 2015, CD000084.
18) de Hundt M. et al. Mode of delivery after successful external cephalic version : a systematic review and meta-analysis. Obstet Gynecol. 123 (6), 2014, 1327-34.
19) Suzuki S. Risk factors for emergency cesarean delivery of the second twin after vaginal delivery of the first twin. J Obstet Gynaecol Res. 35 (3), 2009, 467-71.
20) Wen SW. et al. Occurrence and predictors of cesarean delivery for the second twin after vaginal delivery of the first twin. Obstet Gynecol. 103 (3), 2004, 413-9.
P.314 掲載の参考文献
1) Spong CY. et al. An objective definition of shoulder dystocia : prolonged head-to-body delivery intervals and/or the use of ancillary obstetric maneuvers. Obstet Gynecol. 86, 1995, 433-6.
2) Practice Bulletin No 178 : Shoulder Dystocia. Obstet Gynecol. 129, 2017, e123-33.
3) Acker DB. et al. Risk factors for shoulder dystocia. Obstet Gynecol. 66, 1985, 762.
4) Nesbitt TS. et al. Shoulder dystocia and associated risk factors with macrosomic infants born in California. Am J Obstet Gynecol. 179, 1998, 476.
5) Sandmire HF. et al. Shoulder dystocia : its incidence and associated risk factors. Int J Gynaecol Obstet. 26, 1988, 65.
6) Overland EA, et al. Risk of shoulder dystocia : associations with parity and offspring birthweight : A population study of 1 914 544 deliveries. Acta Obstet Gynecol Scand.91, 2012, 483-8.
7) Sagi-Dain L. et al. The role of episiotomy in prevention and management of shoulder dystocia : a systematic review. Obstet Gynecol Surv. 70, 2015, 354-62.
8) Baxley EG, Gobbo RW. Shoulder Dystocia. American Family Physician. 69, 2004, 1707-14.
9) Gherman RB, et al. The McRoberts' maneuver for the alleviation of shoulder dystocia : how successful is it? Am J Obstet Gynecol. 176, 1997, 656 -61.
10) Hoffman MK, et al. A comparison of obstet- ric maneuvers for the acute management of shoulder dystocia. Consortium on Safe Labor. Obstet Gynecol.117, 2011, 1272-8.
11) Rubin A. Management of shoulder dystocia. JAMA. 189, 1964, 835-7.
12) Woods CE. A principle of physics as applicable to shoulder delivery. Am J Obstet Gynecol. 45, 1943, 796-804.
13) Bruner JP, et al. All-fours maneuver for reducing shoulder dystocia during labor. J Reprod Med. 43, 1998, 439-43.
15) Sandberg EC. The Zavanelli maneuver : a potentially revolutionary method for the resolution of shoulder dystocia. Am J Obstet Gynecol. 152, 1985, 479-84.
16) Sandberg EC. The Zavanelli maneuver : 12 years of recorded experience. Obstet Gynecol. 93, 1999, 312-7.
17) 日本産婦人科学会・日本産婦人科医会編集・監修. "CQ310 巨大児 (出生体重4,000g 以上) が疑われる妊婦への対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 181-5.
18) Reid PC. et al. Symphysiotomy in shoulder dystocia. J Obstet Gynaecol. 19, 1999, 664-6.
19) Chauhan SP, et al. Neonatal brachial plexus palsy : incidence, prevalence, and temporal trends. Semin Perinatol. 38, 2014, 210-8.
20) MacKenzie IZ, et al. Management of shoulder dystocia : trends in incidence and maternal and neonatal morbidity. Obstet Gynecol. 110, 2007, 1059-68.
P.320 掲載の参考文献
1) 厚生労働省. 平成28年度子ども・子育て支援推進調査研究事業「産前・産後の支援のあり方に関する調査研究 妊産婦メンタルヘルスケアマニュアル」. 日本産婦人科医会. 2017.
2) Andreoli C, et al. La depression puerperale precoce : I blues puerperali. Minerva Ginecol. 41, 1989, 173-6.
3) O'Hara MW, et al. Controlled prospective study of postpartum mood disorders : comparison of childbearing and nonchildbearing women. J Abnorm Psychol. 99, 1990, 3-15.
4) Stein GS. The pattern of mental change and body weight change in the first postpartum week. J Psychosom Res. 24, 1980, 165-71.
5) O'Hara MW, et al. Postpartum depression. A role for social network and life stress variables. J Nerv Ment Dis. 171, 1983, 336-41.
6) Davidson JRT, et al. Post-partum mood change in Jamaican women : a description and discussion on its significance. Br J Psychiatry. 121, 1972. 659-63.
7) Ehlert U, et al. Postpartum blues : salivary cortisol and psychological factors. J Psychosom Res. 34, 1990, 319-25.
8) Bolter D, et al. Eine Verlaufsuntersuchung uber Stimmungsschwankungen in den ersten funf Tagen nach der Entibindung. Psychother Med Psychol. 36, 1986, 75-82.
9) Okano T, et al. Cross cultural study of the maternity blues and postpartum depression. J Clin Psychiatry. 33, 1991, 1051-8.
10) Condon JT, Watoson TL. The maternity blues : exploration of a psychological hypothesis. Acta Psychiatr Scand. 76, 1987, 164-71.
11) O'Hara MW, et al. Controlled prospective study of postpartum mood disorder : psychological, environmental, and hormonal variables. J Abnorm Psychol. 100, 1991, 63-73.
12) Kendell RE, et al. Mood changes in the first 3 weeks after childbirth. Journal of affective Disorders. 3, 1981, 317-26.
13) 中野仁雄. 妊産婦の精神面支援とその効果に関する研究. 平成6年度厚生省心身障害研究報告書. 1994 (III).
14) 日本産婦人科学会・日本産婦人科医会編集・監修. "CQ420 産褥精神障害の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会事務局, 2020, 271-4.
15) 吉田敬子. "出産後の精神障害". 母子と家族への援助. 東京, 金剛出版, 2000, 54-85.
16) Hannah P, et al. Links between early post-partum mood and post-natal depression. Br J Psychiatry. 160, 1992, 777-80.
17) Cox JL, et al. Detection of postnatal depression ; Development of the 10 item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 150, 1987, 782-6.
18) 岡野禎治ほか. 日本版エジンバラ産後うつ病自己評価票 (EPDS) の信頼性と妥当性. 精神科診断学. 7 (4), 1996, 525-33.
19) Yonker K A, et al. The management of depression during pregnancy : a report from American Psychiatric Association and American College of Obstetrician and Gynecologists. Gen Hosp Psychiatry. 31, 2009, 403-13.
20) Munk-Olsen T, et al. New parents and mental disorders : a population-based register study. JAMA. 296, 2006, 2582-9.
21) Jones I, et al. Searching for the puerperal trigger : molecular genetic studies of bipolar affective puerperal psychosis. Psychopharmacol Bull. 40, 2007, 115-28.
22) Ahokas A, et al. Positive treatment effect of estradiol in postpartum psychosis : a pilot study. J Clin Psychiatry. 61, 2000. 166-9.
23) Boyce P, et al. Puerperal psychosis. Arch Womens Ment Health. 13, 2010, 45-7.
24) Steiner M, et al. Propranolol versus chlorpromazine in the treatment of psychoses associated with childbearing. Psychiatr Neurol Neurochir. 76, 1973, 421-6.
25) Focht A, et al. Electroconvulsive therapy (ETC) in the treatment of postpartum psychosis. J ECT. 28, 2012, 31-3.
26) Brockington IF. 母性とメンタルヘルス. 岡野禎治ほか訳. 東京, 日本評論社, 1999, 424p.
27) Megan Galballyほか. 妊婦の精神疾患と向精神薬. 岡野禎治ほか訳. 東京, 南山堂, 2018, 228p.
P.325 掲載の参考文献
1) 日本産科婦人科学会編. "産褥熱". 産科婦人科用語集・用語解説集. 改訂第4版. 東京, 金原出版, 2018, 104.
2) 日本産科婦人科学会編. 産婦人科専門医のための必修知識 2020年度版. 東京, 日本産科婦人科学会, 2018, B173-4. "異常産褥 : 産褥熱".
3) 日本集中治療医学会. 日本版敗血症診療ガイドライン 2020. 日本集中治療医学会雑誌. 28 (supplement), 2021, S21.
4) 日本感染症学会. "毒素性ショック症候群 (toxic shock syndrome ; TSS)". 症状からアプローチするインバウンド感染症への対応 : 感染症クイック・リファレンス. https://www.kansensho.or.jp/ref/d45.html [2021. 11. 1].
5) 日本産婦人科感染症学会編. "子宮内膜炎・子宮筋層炎・子宮傍結合織炎". 産婦人科感染症マニュアル. 東京, 金原出版, 2018, 85-93.
6) Mackeen AD. et al. Antibiotic regimens postpartum endometritis. Cochrane Database of Systematic Reviews. 2015, (2), CD001067.
7) Cunningham FG. et al. "Puerperal complications". Williams Obstetrics 25th edition. McGraw-Hill, 2018, 666-79.

第3章 胎児・新生児の管理

P.335 掲載の参考文献
1) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ106-2 産科超音波検査を実施するにあたっての留意点は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 82-5.
2) Salomon LJ. et al. ISUOG practice guidelines : performance of first-trimester fetal ultrasound scan. Ultrasound Gynecol 41 (1). 2013, 102-13.
3) Rossi AC, Prefumo F. Accuracy of ultrasonography ata 11-14 weeks of gestation for detection of fetal structural anomalies ; a systematic review. Obstet Gynecol. 122 (6), 2013, 1160-7.
4) 超音波による胎児形態の標準的評価法. 日本超音波医学会用語・診断基準委員会 胎児超音波スクリーニングガイドライン作成小委員会 2022年3月11日公示
5) Tonni G. et al. Early Detection of Cleft Lip by Three-Dimensional Transvaginal Ultrasound in Niche Mode in a Fetus With Trisomy 18 Diagnosed by Celocentesis. Cleft Palate Craniofac J. 53 (6), 2016, 745-8.
6) Wilhelm L, Borgers H. The "equals sign" : a novel marker in the diagnosis of fetal isolated cleft palate. Ultrasound Obstet Gynecol. 36 (4), 2010, 439-44.
7) Dabadie A. et al. Added value of MRI for the prenatal diagnosis of isolated orofacial clefts and comparison with ultrasound. Diagn Interv Imaging. 97 (9), 2016, 915-21.
8) Sniders RJM, Nicolaides KH. Ultrasound markers for fetal chromosomal defects. Parthenon Publishing Group, London,1996, 22-3.
9) Nicolaides KH. et al. Fetal nuchal translucency : ultrasound screening for chromosomal defect in first trimester of pregnancy. BMJ. 304 (6831), 1992, 867-9.
10) Hyett JA. et al. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol. 10 (4), 1997, 242-6.
11) Souka AP. et al. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol. 18 (1), 2001, 9-17.
P.340 掲載の参考文献
1) Stocker JT. et al. Congenital cystic adenomatoid malformation of the lung : classification and morphologic spectrum. Hum Pathol 1997 ; 8 : 155-71.
2) M Kitaichi. et al. Congenital pulmonary airway malformation : a new name for an expanded classification of congenital cystic adenomatoid malformation of the lung. Histopathology. 41 (2), 2002, 424-58.
3) Adzick NS, et al. Fetal cystic adenomatoid malformation : prenatal diagnosis and natural history. J Pediatr Surg. 20, 1985, 483-8.
4) Crombleholme TM. et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. J Pediatr Surg. 37 (3), 2002, 331-8.
5) Litwinska M. et al. Thoracoamniotic shunts in macrocystic lung lesions : case series and review of the literature. Fetal Diagn Ther. 41 (3), 2017, 179-83.
6) Loh KC. et al. Microcystic congenital pulmonary airway malformation with hydrops fetalis : steroids vs open fetal resection. J Pediatr Surg. 47 (1), 2012, 36-9.
7) Morris LM. et al. High-risk fetal congenital pulmonary airway malformations have a variable response to steroids. J Pediatr Surg. 44 (1), 2009, 60-5.
8) 市田蕗子. 先天性心疾患の疫学. 日本小児循環器学会雑誌. 26, 2010, 2-3.
P.348 掲載の参考文献
1) Gilbert MW. et al. Amniotic fluid dynamics. Fetal Med Rev. 3, 1991, 89-104.
2) 河崎正裕ほか. 出生前超音波検査にて特徴的画像を呈した上行結腸閉鎖症の一例. 日本周産期・新生児医学会雑誌. 45, 2009, 152-55.
3) Sase M. et al. Fetal gastric size in normal and abnormal pregnancies. Ultrasound Obstet Gynecol. 19, 2002, 467-70.
4) Nyberg DA. et al. Fetal bowel : normal sonographic findings. J Ultrasound Med. 6, 1987, 3-6.
5) Bianchi DW. et al. eds. "大腸閉鎖". ニューイングランド周産期マニュアル. 改訂2版. 南山堂. 東京. 2011, 624-27.
6) Nadel A. "Ultrasound Evaluation of Fetal Gastrointestinal Tract and Abdominal Wall". Callen's Ultrasonography and Gynecology in Obstetrics and Gynecology. 6th ed. New York, Elsevier, 2017, 460-502.
7) 浅田裕美ほか. Transient Abnormal Myelopoiesisと出生前診断した21 trisomyの1例. 超音波医学. 30, 2003, J549-53.
8) 河崎正裕, 佐世正勝. 出生前診断された右臍静脈開存を合併した左側胆嚢の3例. 小児外科. 40, 2008, 1404-07.
9) Petrikovsky B. et al. Sludge in fetal gallbladder : natural history and neonatal outcome. Br J Radiol. 69, 1996, 1017-8.
10) 根津優子ほか. 小児外科疾患を出生前診断する契機となった所見に関する検討. 現代産婦人科. 59, 2010, 33-7.
11) Sase M. et al. Gastric emptying cycles in the human fetus. Am J Obstet Gynecol. 193, 2005, 1000-4.
12) Pedersen RN. et al. Oesophageal atresia : prevalence, prenatal diagnosis and associated anomalies in 23 European regions. Arch Dis Child. 97, 2012, 227-32.
13) Nyberg DA. et al. "Chromosomal abnormalities". Diagnostic Imaging of Fetal Anomalies. Nyberg DA. et al. eds. Philadelphia, Lippincott Williams & Wilkins, 2003, 86-906.
14) 佐世正勝ほか. いつから羊水の主成分が胎児尿となるか? : 羊水過少と先天性腎泌尿器異常の関連. 産婦人科の実際. 63, 2014, 101-4.
15) Odibo AO., Dicke JM. "Fetal genitourinary tract". Ultrasonography in Obstetrics and Gynecology. 6th ed. New York, Elsevier, 2017, 503-38.
P.353 掲載の参考文献
1) Mortier GR. et al. Nosology and classification of genetic skeletal disorders : 2019 revision. Am J Med Genet. 179, 2019, 2393-419.
2) 西村玄. 骨系統疾患X 線アトラス : 遺伝性骨疾患の鑑別診断. 東京, 医学書院, 1993, 240p.
P.358 掲載の参考文献
1) ACOG Committee Opinion No.326. Inappropriate use of the term fetal distress and birth asphyxia. December, 2005 (Replaces ACOG Committee Opinion No.197, February 1998).
2) ACOG Practice Bulletin No.70. Intrapartum fetal heart rate monitoring, December, 2005.
3) 日本産科婦人科学会周産期委員会報告. 胎児心拍数図の用語及び定義検討小委員会. 日本産科婦人科学会雑誌. 55, 2003, 1205-16.
4) 日本産科婦人科学会周産期委員会. 胎児心拍数波形の分類に基づく分娩時胎児管理の指針 (2010年版). 日本産科婦人科学会雑誌. 62, 2010, 2068-73.
5) Okai T. et al. Intrapartum management guidelines based on fetal heart rate pattern classification. J Obstet Gynecol Res. 36, 2010, 925-8.
6) 日本産科婦人科学会/日本産婦人科医会 編集・監修. "CQ411 分娩監視モニターの読み方・対応は? ". 産婦人科診療ガイドライン : 産科編 2011. 2011, 199-205.
7) 日本産科婦人科学会/日本産婦人科医会 編集・監修. 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 228-32. "CQ411 胎児心拍数陣痛図の評価法とその対応は? ".
8) Electronic fetal heart rate monitoring : Research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol. 177, 1997, 1385-90.
9) Macones GA. et al. The 2008 NICHD workshop report on electronic fetal monitoring. Obstet Gynecol. 112, 2008, 661-6.
10) 日本産科婦人科学会周産期委員会 胎児機能不全診断基準の妥当性検討に関する小委員会 (委員長 : 池田智明). II. 「胎児心拍数図に関する用語・定義」の改定に関する提案. 平成24年6月13日.
11) 日本産科婦人科学会/日本産婦人科医会 編集・監修. 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 186-7. "CQ311 人工羊水注入については? ".
12) Garite TJ. et al. Fetal heart rate patterns and fetal distress in fetuses with congenital anomalies. Obstet Gynecol. 53, 1979, 716-20.
13) Ueda K. et al. Intrapartum fetal heart rate monitoring in cases of congenital heart disease. Am J Obstet Gynecol. 201, 2009, 64.e1-6.
14) Kaneko M. et al. Intrapartum fetal heart rate monitoring in cases of cytomegalovirus infection. Am J Obstet Gynecol. 191, 2004, 1257-62.
15) Kodama Y. et al. Intrapartum fetal heart rate patterns in infants (≧ 34 weeks) with poor neurological outcome. Early Hum Dev. 85, 2009, 235-8.
P.362 掲載の参考文献
1) Manning FA. et al. Qualitative amniotic fluid volumes in normal pregnancy. Am J Obstet Gynecol. 139, 1981, 254-8.
2) Phelan JP. et al. Amniotic fluid volumes assessment with the four-quadrant technique at 36-42 week's gestation. J Reprod Med. 32, 1987, 540-2.
3) Cunningham FG. et al. eds. "Disorders of amniotic fluid volume". Williams Obstetrics. 23rd ed. New York, McGraw-Hill, 2010, 490-9.
4) Dorleijn DM. et al. Idiopathic polyhydramnios and postnatal findings. J Matern Fetal Neonatal Med. 22, 2009, 315-20.
5) De Santis M. et al. Transabdominal amnioinfusion treatment of severe oligohydramnios in preterm premature rupture of membranes at less than 26 gestational weeks. Fetal Diagn Ther. 18, 2003, 412-7.
6) Yoon BH. et al. Association of oligohydramnios in women with preterm premature rupture of membranes with an inflammatory response in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol. 181, 1999, 784-8.
7) Quintero RA. et al. Stage-based treatment of twin-twin transfusion syndrome. Am J Obstet Gynecol. 188, 2003, 1333-40.
P.367 掲載の参考文献
1) 日本産科婦人科学会・日本産婦人科医会編集・監修. "CQ307-1 胎児発育不全 (FGR) のスクリーニングは? " "CQ307-2 胎児発育不全 (FGR) の取り扱いは? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 157-63.
2) Baschat AA. Neurodevelopment following fetal growth restriction and its relationship with antepartum parameters of placental dysfunction. Ultrasound Obstet Gynecol. 37, 2011, 501-14.
3) American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 227 : fetal growth restriction. Obstet Gynecol. 137 (2), 2021, e16-e28.
4) Pels A. et al. Early-onset fetal growth restriction : A systematic review on mortality and morbidity. Acta Obstet Gynecol Scand. 99 (2), 2020, 153-66.
5) 日本産科婦人科学会周産期委員会. 委員会提案 : 超音波胎児計測の標準化と日本人の基準値. 日本産婦人科学会雑誌. 57 (1), 2005, 92-117.
6) 日本産科婦人科学会編集・監修. 産科婦人科用語集・用語解説集改訂. 第4版. 東京, 日本産科婦人科学会, 2018.
7) American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 700 : Method for Estimating Due Date. Obstet Gynecol. 129 (5), 2017, e150-4.
8) 前田隆嗣. 早産期FGRの予後に関わる因子と当院でのterminationのポイント. 日本新生児成育医学会雑誌. 31 (3), 2019, 637p.
9) Thornton JG. et al. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT) : multicentred randomised controlled trial. Lancet. 364 (9433), 2004, 513-20.
10) GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus : short term outcomes and Bayesian interpretation. BJOG. 110 (1), 2003, 27-32.
11) Boers KE. et al. Induction versus expectant monitoring for intrauterine growth restriction at term : randomised equivalence trial (DIGITAT). BMJ. 2010. 341 : c7087.
12) Lees CC. et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE) : a randomised trial. Lancet. 385 (9983), 2015, 2162-72.
13) Visser GHA. et al. Fetal monitoring indications for delivery and 2-year outcome in 310 infants with fetal growth restriction delivered before 32 weeks' gestation in the TRUFFLE study. Ultrasound Obstet Gynecol. 50 (3), 2017, 347-52.
14) Roberge S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction : systematic review and meta-analysis. Am J Obstet Gynecol. 216 (2), 2017, 110-20.e6.
15) Rolnik DL. et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 377, 2017, 613-22.
16) American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 743 : Low-Dose Aspirin Use During Pregnancy. Obstet Gynecol. 132 (1), 2018, e44-e52.
P.371 掲載の参考文献
1) ACOG Committee on Practice Bulletins Obstetrics. Macrosomia : ACOG Practice Bulletin, Number 216. Obstet Gynecol. 135 (1), 2020, e18-e35.
2) Morikawa M. et al. Fetal macrosomia in Japanese women. J Obstet Gynaecol Res. 39 (5), 2013, 960-5.
3) 日本超音波医学会 平成14・15年度 用語・診断基準委員会. 超音波胎児計測の標準化と日本人の基準値. 超音波医学. 30 (3), 2003, 415-41.
4) Barel O. et al. Assessment of the accuracy of multiple sonographic fetal weight estimation formulas : a 10-year experience from a single center. J Ultrasound Med. 32 (5), 2013, 815-23.
5) Chauhan SP. et al. Suspicion and treatment of the macrosomic fetus : a review. Am J Obstet Gynecol. 193 (2), 2005, 332-46.
6) 日本産科婦人科学会/日本産婦人科医会編集・監修. "CQ310 巨大児 (出生体重4,000g以上) が疑われる妊婦への対応は? ". 産婦人科診療ガイドライン : 産科編 2020. 東京, 日本産科婦人科学会, 2020, 181-5.
7) Langer O. et al. Shoulder dystocia : should the fetus weighing greater than or equal to 4000 grams be delivered by cesarean section?. Am J Obstet Gynecol. 165 (4 Pt 1), 1991, 831-7.
8) The HAPO study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome Study. N Engl J Med. 358 (19), 2008, 1991-2002.
9) Pedersen J. Weight and length at birth of infants of diabetic mothers. Acta Endocrinol (Copenh). 16 (4), 1954, 330-42.
10) Cunningham FG. et al. "Diabetes Mellitus". Williams Obstetrics. 24th ed. New York, McGraw-Hill, 2014, 1125-46.
11) Langer O. et al. Gestational diabetes : the consequences of not treating. Am J Obstet Gynecol. 192 (4), 2005, 989-97.
12) Catalano PM. et al. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic. Am J Obstet Gynecol. 204 (6), 2011, 479-87.
13) Bowers K. et al. Gestation